carbamazepine has been researched along with Depression, Endogenous in 174 studies
Carbamazepine: A dibenzazepine that acts as a sodium channel blocker. It is used as an anticonvulsant for the treatment of grand mal and psychomotor or focal SEIZURES. It may also be used in the management of BIPOLAR DISORDER, and has analgesic properties.
carbamazepine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine carrying a carbamoyl substituent at the azepine nitrogen, used as an anticonvulsant.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this study was to evaluate the effect of carbamazepine on chronic pain in patients with major depression." | 9.08 | Effect of carbamazepine on pain scores of unipolar depressed patients with chronic pain: a trial of off-on-off-on design. ( Ishihara, H; Kudoh, A; Matsuki, A, 1998) |
| "Sixteen female outpatients with borderline personality disorder and prominent behavioral dyscontrol, but without a current episode of major depression, were studied in a double-blind, crossover trial of placebo and the following four active medications: alprazolam (average dose, 4." | 9.06 | Pharmacotherapy of borderline personality disorder. Alprazolam, carbamazepine, trifluoperazine, and tranylcypromine. ( Cowdry, RW; Gardner, DL, 1988) |
| " We describe two patients with idiopathic generalized epilepsy in whom nonconvulsive status epilepticus, aggravated by carbamazepine, was misdiagnosed as psychiatric disorder." | 7.73 | Nonconvulsive status epilepticus precipitated by carbamazepine presenting as dissociative and affective disorders in adolescents. ( D'Arcangelo, G; Guerrini, R; Marini, C; Masi, G; Parmeggiani, L, 2005) |
| "One schizophrenic and two manic-depressive patients who after the administration of zotepine, a new antipsychotic and antimanic drug, developed alopecia areata, a kind of autoimmune disease, are reported." | 7.68 | Three cases of alopecia areata induced by zotepine. ( Ishikura, T; Jibiki, I; Kubota, T, 1993) |
| "The effect of carbamazepine on body weight was studied in 24 patients with affective illness." | 7.67 | Effect of carbamazepine on body weight in affectively ill patients. ( Joffe, RT; Post, RM; Uhde, TW, 1986) |
| "A case of thrombocytopenia associated with carbamazepine use is reported, and previous reports of adverse hematologic effects in patients taking carbamazepine are discussed." | 7.67 | Thrombocytopenia associated with carbamazepine: case report and review. ( Baciewicz, G; Yerevanian, BI, 1984) |
| "The authors assessed 20 carbamazepine-treated patients for the development of hyponatremia." | 7.67 | Carbamazepine and hyponatremia in patients with affective disorder. ( Camille, Y; Iskandar, H; Nastase, C; Yassa, R, 1988) |
| "The effects on serum electrolytes of carbamazepine, an acute and prophylactic treatment for manic-depressive illness, were assessed in subjects with primary affective disorder." | 7.67 | Effects of carbamazepine on serum electrolytes in affectively ill patients. ( Joffe, RT; Post, RM; Uhde, TW, 1986) |
| "Carbamazepine has been used to treat mania for over 2 decades." | 6.71 | A multicenter, randomized, double-blind, placebo-controlled trial of extended-release carbamazepine capsules as monotherapy for bipolar disorder patients with manic or mixed episodes. ( Kalali, AH; Ketter, TA; Weisler, RH, 2004) |
| " for 10 days) on the steady-state plasma concentrations of Oxcarbazepine (OXC), its active metabolite 10, 11-dihydro-10-hydroxy-carbazepine (MHD) and the corresponding diol (DHD) were studied in a randomized, double-blind cross-over placebo-controlled trial in 6 epileptic patients stabilized on a fixed dosage of OXC." | 6.67 | Effects of the antidepressant drug viloxazine on oxcarbazepine and its hydroxylated metabolites in patients with epilepsy. ( Artesi, C; Di Perri, R; Fazio, A; Oteri, G; Perucca, E; Pisani, F; Xiao, B, 1994) |
| "Because patients with borderline personality disorder show prominent affective symptomatology on the one hand and symptoms suggestive of an epileptoid disorder on the other, carbamazepine was included in a multidrug, placebo-controlled, double-blind study." | 6.66 | Development of melancholia during carbamazepine treatment in borderline personality disorder. ( Cowdry, RW; Gardner, DL, 1986) |
| "A 34-year-old woman treated for a major depressive disorder experienced NMS with a phenothiazine." | 5.30 | Carbamazepine in the treatment of neuroleptic malignant syndrome. ( Cottencin, O; Goudemand, M; Maron, M; Rascle, C; Thomas, P; Vaiva, G, 1998) |
| "The purpose of this study was to evaluate the effect of carbamazepine on chronic pain in patients with major depression." | 5.08 | Effect of carbamazepine on pain scores of unipolar depressed patients with chronic pain: a trial of off-on-off-on design. ( Ishihara, H; Kudoh, A; Matsuki, A, 1998) |
| "Bupropion (BUP) may be less likely than other antidepressants to cause switches into mania and rapid cycling, suggesting utility in bipolar disorder." | 5.08 | Carbamazepine but not valproate induces bupropion metabolism. ( Callahan, AM; Chao, J; George, MS; Hinton, ML; Jenkins, JB; Ketter, TA; Marangell, LB; Pazzaglia, PJ; Post, RM; Schroeder, DH, 1995) |
| "Sixteen female outpatients with borderline personality disorder and prominent behavioral dyscontrol, but without a current episode of major depression, were studied in a double-blind, crossover trial of placebo and the following four active medications: alprazolam (average dose, 4." | 5.06 | Pharmacotherapy of borderline personality disorder. Alprazolam, carbamazepine, trifluoperazine, and tranylcypromine. ( Cowdry, RW; Gardner, DL, 1988) |
| "The comparative usefulness of carbamazepine and lithium carbonate in the acute and prophylactic management of DSM-III diagnosed major affective, schizoaffective, or schizophreniform psychoses was investigated in a 3-year, prospective double-blind randomized trial with 83 in- and outpatients." | 5.06 | The comparative efficacy and safety of carbamazepine versus lithium: a randomized, double-blind 3-year trial in 83 patients. ( Akiskal, HS; Cassano, GB; Lazzerini, F; Lenzi, A; Placidi, GF, 1986) |
| " As the result of the detailed analysis of the literature the author recommends lamotrigine, carbamazepine and oxcarbazepine as first choice antiepileptic drug for epileptic patients suffering from depressive disorder, too." | 4.84 | [Effects of antiepileptic drugs on mood of people with epilepsy]. ( Rajna, P, 2007) |
| "Mood-stabilizing drugs including lithium, anticonvulsants, and antipsychotics have established effects in the management of bipolar disorder, especially in mania." | 4.80 | Mood-stabilizing drugs in depression. ( Shelton, RC, 1999) |
| " We describe two patients with idiopathic generalized epilepsy in whom nonconvulsive status epilepticus, aggravated by carbamazepine, was misdiagnosed as psychiatric disorder." | 3.73 | Nonconvulsive status epilepticus precipitated by carbamazepine presenting as dissociative and affective disorders in adolescents. ( D'Arcangelo, G; Guerrini, R; Marini, C; Masi, G; Parmeggiani, L, 2005) |
| "The purpose of this study was to determine the occurrence of leukopenia and other blood dyscrasias associated with psychiatric use of carbamazepine and valproate." | 3.69 | Blood dyscrasias with carbamazepine and valproate: a pharmacoepidemiological study of 2,228 patients at risk. ( Baldessarini, RJ; Castillo, J; Kando, JC; Tohen, M; Zarate, C, 1995) |
| " In this paper we describe two patients with comorbid epilepsy, major depression, and panic disorder, whose serum citalopram levels increased and antidepressant response changed when concurrent carbamazepine treatment was substituted with oxcarbazepine." | 3.69 | Substituting carbamazepine with oxcarbazepine increases citalopram levels. A report on two cases. ( Koponen, H; Leinonen, E; Lepola, U, 1996) |
| "One schizophrenic and two manic-depressive patients who after the administration of zotepine, a new antipsychotic and antimanic drug, developed alopecia areata, a kind of autoimmune disease, are reported." | 3.68 | Three cases of alopecia areata induced by zotepine. ( Ishikura, T; Jibiki, I; Kubota, T, 1993) |
| "The effect of carbamazepine on body weight was studied in 24 patients with affective illness." | 3.67 | Effect of carbamazepine on body weight in affectively ill patients. ( Joffe, RT; Post, RM; Uhde, TW, 1986) |
| "The authors assessed 20 carbamazepine-treated patients for the development of hyponatremia." | 3.67 | Carbamazepine and hyponatremia in patients with affective disorder. ( Camille, Y; Iskandar, H; Nastase, C; Yassa, R, 1988) |
| "A thyrotropin (thyroid-stimulating hormone; TSH) stimulation test with thyroid-releasing hormone (TRH) was performed on six patients with a DSM-III diagnosis of major depressive disorder, both before and during a trial of carbamazepine." | 3.67 | The effects of carbamazepine on the thyrotropin response to thyrotropin-releasing hormone. ( Gold, PW; Joffe, RT; Post, RM; Uhde, TW, 1984) |
| "The responses of 16 patients with major depressive disorder to one night's sleep deprivation and a subsequent double-blind, placebo-controlled trial of carbamazepine were compared." | 3.67 | Relationship of response to sleep deprivation and carbamazepine in depressed patients. ( Joffe, RT; Post, RM; Roy-Byrne, P; Uhde, TW, 1984) |
| "A case of thrombocytopenia associated with carbamazepine use is reported, and previous reports of adverse hematologic effects in patients taking carbamazepine are discussed." | 3.67 | Thrombocytopenia associated with carbamazepine: case report and review. ( Baciewicz, G; Yerevanian, BI, 1984) |
| "Hematological indices were measured in 8 patients with bipolar disorder during carbamazepine and carbamazepine-lithium combination treatment." | 3.67 | Hematological effects of lithium potentiation of carbamazepine in patients with affective illness. ( Joffe, RT, 1988) |
| "The effects on serum electrolytes of carbamazepine, an acute and prophylactic treatment for manic-depressive illness, were assessed in subjects with primary affective disorder." | 3.67 | Effects of carbamazepine on serum electrolytes in affectively ill patients. ( Joffe, RT; Post, RM; Uhde, TW, 1986) |
| "Carbamazepine has been used to treat mania for over 2 decades." | 2.71 | A multicenter, randomized, double-blind, placebo-controlled trial of extended-release carbamazepine capsules as monotherapy for bipolar disorder patients with manic or mixed episodes. ( Kalali, AH; Ketter, TA; Weisler, RH, 2004) |
| " Therefore, despite considerable reductions in total serum levels of IMI and DMI, but when the unchanged free fraction concentration of these compounds is maintained, a dosage elevation of IMI does not seem to be necessary after CBZ addition to TCA therapy." | 2.70 | Pharmacokinetic interaction between imipramine and carbamazepine in patients with major depression. ( Szymura-Oleksiak, J; Wasieczko, A; Wyska, E, 2001) |
| "All 10 patients tolerated the addition of an MAOI well, and mean self-rated side effect scores did not change significantly." | 2.68 | Addition of monoamine oxidase inhibitors to carbamazepine: preliminary evidence of safety and antidepressant efficacy in treatment-resistant depression. ( Ketter, TA; Parekh, PI; Post, RM; Worthington, K, 1995) |
| "The prophylaxis of unipolar depression is still controversial." | 2.67 | Carbamazepine in the prophylaxis of major depression: a 5-year follow-up. ( Barnas, C; Fleischhacker, WW; Schwitzer, J; Stuppaeck, CH, 1994) |
| "Carbamazepine treatment was consistently and significantly associated with increased cerebrospinal fluid thyrotropin-releasing hormone levels (P < ." | 2.67 | Carbamazepine increases cerebrospinal fluid thyrotropin-releasing hormone levels in affectively ill patients. ( Bissette, G; George, MS; Huggins, T; Marangell, LB; Pazzaglia, P; Post, RM, 1994) |
| " for 10 days) on the steady-state plasma concentrations of Oxcarbazepine (OXC), its active metabolite 10, 11-dihydro-10-hydroxy-carbazepine (MHD) and the corresponding diol (DHD) were studied in a randomized, double-blind cross-over placebo-controlled trial in 6 epileptic patients stabilized on a fixed dosage of OXC." | 2.67 | Effects of the antidepressant drug viloxazine on oxcarbazepine and its hydroxylated metabolites in patients with epilepsy. ( Artesi, C; Di Perri, R; Fazio, A; Oteri, G; Perucca, E; Pisani, F; Xiao, B, 1994) |
| "Because patients with borderline personality disorder show prominent affective symptomatology on the one hand and symptoms suggestive of an epileptoid disorder on the other, carbamazepine was included in a multidrug, placebo-controlled, double-blind study." | 2.66 | Development of melancholia during carbamazepine treatment in borderline personality disorder. ( Cowdry, RW; Gardner, DL, 1986) |
| "Carbamazepine has a unique spectrum of clinical efficacy in paroxysmal pain syndromes and epilepsy, as well as in affective illness." | 2.65 | Biochemical effects of carbamazepine: relationship to its mechanisms of action in affective illness. ( Ballenger, JC; Gold, PW; Post, RM; Rubinow, DR; Uhde, TW, 1983) |
| "A major challenge in the treatment of bipolar depression is the tendency for antidepressant medications, particularly tricyclic antidepressants, to precipitate episodes of mania, or to increase cycle frequency or symptom intensity." | 2.44 | The role of mood stabilisers in the treatment of the depressive facet of bipolar disorders. ( Bourin, M; Prica, C, 2007) |
| "A case of acute renal failure occurring during treatment with carbamazepine is reported." | 2.38 | [Acute renal failure complicating carbamazepine hypersensitivity]. ( Fournier, A; Lambert, M, 1992) |
| "Conclusions Depressive disorders are common, underdiagnosed and undertreated in patients with refractory MTLE." | 1.48 | Depressive disorders in patients with pharmaco-resistant mesial temporal lobe epilepsy. ( Cendes, F; de Oliveira Cardoso, TAM; Gonçalves, EB; Yasuda, CL, 2018) |
| "Twenty-one inpatients with recurrent endogenous depression received MCB (150 mg t." | 1.35 | Moclobemide monotherapy vs. combined therapy with valproic acid or carbamazepine in depressive patients: a pharmacokinetic interaction study. ( Miljkovic, B; Pokrajac, M; Rakic Ignjatovic, A; Timotijevic, I; Todorovic, D, 2009) |
| " Ten CYP2D6 genotyped and depressive (F32x and F33x, ICD-10) patients participated in an open study on the pharmacokinetic and pharmacodynamic consequences of a carbamazepine augmentation in VEN non-responders." | 1.32 | Combination therapy with venlafaxine and carbamazepine in depressive patients not responding to venlafaxine: pharmacokinetic and clinical aspects. ( Baumann, P; Brawand-Amey, M; Brocard, M; Ciusani, E; Eap, CB; Zullino, DF, 2004) |
| "The neuroanatomy and neurobiology of PTSD will be discussed to illustrate the interface between: (1) the neural correlates of physical and sexual abuse and the presence of PTSD in adult women, and (2) the neurophysiologic pathway for healing through therapy aimed at empowering the trauma patient to take constructive action." | 1.31 | Women with PTSD: the psychodynamic aspects of psychopharmacologic and "hands-on" psychiatric management. ( Sageman, S, 2002) |
| "One patient had moderate confusion, and the other mild confusion and hypomania." | 1.30 | Combined valproate or carbamazepine and electroconvulsive therapy. ( Baraibar, G; Tohen, M; Zarate, CA, 1997) |
| "Two had organic catatonic disorder and the third organic depressive disorder." | 1.30 | The treatment of stupor associated with MRI evidence of cerebrovascular disease. ( Herzberg, J; Ranger, M; Spear, J, 1997) |
| "A 34-year-old woman treated for a major depressive disorder experienced NMS with a phenothiazine." | 1.30 | Carbamazepine in the treatment of neuroleptic malignant syndrome. ( Cottencin, O; Goudemand, M; Maron, M; Rascle, C; Thomas, P; Vaiva, G, 1998) |
| "The prophylaxis of unipolar depression is still a controversial subject." | 1.29 | The role of carbamazepine in the prophylaxis of unipolar depression. ( Barnas, C; Fleischhacker, WW; Schwitzer, J; Stuppaeck, C, 1993) |
| "Clozapine can induce dose-dependent myoclonus." | 1.29 | Myoclonus in patients treated with clozapine: a case series. ( Bak, TH; Bauer, M; Hellweg, R; Reischies, FM; Schaub, RT, 1995) |
| "Its influence on the course of affective psychoses was studied in 67 patients in long-term treatment." | 1.28 | Political change and course of affective psychoses: Berlin 1989-90. ( Bohlken, J; Priebe, S, 1991) |
| "Carbamazepine treatment also produced an increase in the growth hormone response to subcutaneous administration of the dopamine agonist apomorphine hydrochloride (5 micrograms/kg)." | 1.28 | Effects of carbamazepine on dopamine- and serotonin-mediated neuroendocrine responses. ( Cowen, PJ; Elphick, M; Yang, JD, 1990) |
| "Treatment with carbamazepine reduced CSF somatostatin (p less than ." | 1.27 | CSF somatostatin in affective illness and normal volunteers. ( Ballenger, JC; Gold, PW; Post, RM; Rubinow, DR, 1985) |
| "Levels of carbamazepine and its -10,11-epoxide metabolite were measured in plasma and CSF of affectively ill patients treated only with carbamazepine for an average of 33 days at an average dosage of 1,055 mg/day." | 1.27 | Carbamazepine and its -10,11-epoxide metabolite in plasma and CSF. Relationship to antidepressant response. ( Ballenger, JC; Bunney, WE; Chatterji, DC; Greene, RF; Post, RM; Uhde, TW, 1983) |
| " Subacute and chronic administration of imipramine (4 or 15 mg/kg) decreased immobility of rats in the behavioral despair model." | 1.27 | The effects of carbamazepine on two animal models of depression. ( Barros, HM; Leite, JR, 1987) |
| "The bioavailability of dexamethasone (DEX) has recently been demonstrated to be a critical factor in determining Dexamethasone Suppression Test (DST) status in psychiatric patients." | 1.27 | Dexamethasone bioavailability: implications for DST research. ( Lowy, MT; Meltzer, HY, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 64 (36.78) | 18.7374 |
| 1990's | 76 (43.68) | 18.2507 |
| 2000's | 25 (14.37) | 29.6817 |
| 2010's | 9 (5.17) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gonçalves, EB | 1 |
| de Oliveira Cardoso, TAM | 1 |
| Yasuda, CL | 1 |
| Cendes, F | 1 |
| Müller, DJ | 1 |
| Brandl, EJ | 1 |
| Degenhardt, F | 1 |
| Domschke, K | 1 |
| Grabe, H | 1 |
| Gruber, O | 1 |
| Hebebrand, J | 1 |
| Maier, W | 1 |
| Menke, A | 1 |
| Riemenschneider, M | 1 |
| Rietschel, M | 1 |
| Rujescu, D | 1 |
| Schulze, TG | 1 |
| Tebartz van Elst, L | 1 |
| Tüscher, O | 1 |
| Deckert, J | 1 |
| Silva, EF | 1 |
| Silva, AI | 1 |
| Asth, L | 1 |
| Souza, LS | 1 |
| Zaveri, NT | 1 |
| Guerrini, R | 2 |
| Calo', G | 1 |
| Ruzza, C | 1 |
| Gavioli, EC | 1 |
| Ramos-Zúñiga, R | 1 |
| Pérez-Gómez, HR | 1 |
| Gaytán-Martínez, LA | 1 |
| Vega-Ruiz, B | 1 |
| Soto-Rodríguez, S | 1 |
| Rochín-Mozqueda, A | 1 |
| Shansis, FM | 1 |
| Reche, M | 1 |
| Capp, E | 1 |
| Pearlstein, T | 1 |
| Sümegi, A | 1 |
| Rakic Ignjatovic, A | 1 |
| Miljkovic, B | 1 |
| Todorovic, D | 1 |
| Timotijevic, I | 1 |
| Pokrajac, M | 1 |
| Duggal, HS | 1 |
| Singh, I | 1 |
| Liu, HY | 1 |
| Potter, MP | 1 |
| Woodworth, KY | 1 |
| Yorks, DM | 1 |
| Petty, CR | 1 |
| Wozniak, JR | 1 |
| Faraone, SV | 1 |
| Biederman, J | 1 |
| Toledo, M | 1 |
| Munuera, J | 1 |
| Salas-Puig, X | 1 |
| Santamarina, E | 1 |
| Lacuey, N | 1 |
| Rovira, A | 1 |
| Navarro, R | 1 |
| Llamas, M | 1 |
| Gallo, E | 1 |
| Sánchez-Pérez, J | 1 |
| Fraga, J | 1 |
| García-Diez, A | 1 |
| De León, OA | 1 |
| Sageman, S | 1 |
| Raja, M | 1 |
| Azzoni, A | 1 |
| Weisler, RH | 1 |
| Kalali, AH | 1 |
| Ketter, TA | 5 |
| Yatham, LN | 1 |
| Hirschfeld, RM | 1 |
| Kasper, S | 2 |
| Ciusani, E | 1 |
| Zullino, DF | 1 |
| Eap, CB | 1 |
| Brawand-Amey, M | 1 |
| Brocard, M | 1 |
| Baumann, P | 2 |
| Gajwani, P | 1 |
| Forsthoff, A | 1 |
| Muzina, D | 1 |
| Amann, B | 1 |
| Gao, K | 1 |
| Elhaj, O | 1 |
| Calabrese, JR | 2 |
| Grunze, H | 1 |
| Howland, RH | 1 |
| Soultanian, C | 1 |
| Perisse, D | 1 |
| Révah-Levy, A | 1 |
| Luque, R | 1 |
| Mazet, P | 1 |
| Cohen, D | 1 |
| Marini, C | 1 |
| Parmeggiani, L | 1 |
| Masi, G | 1 |
| D'Arcangelo, G | 1 |
| Obermoser, G | 1 |
| Zelger, B | 1 |
| Bourin, M | 1 |
| Prica, C | 1 |
| Rajna, P | 1 |
| Zhang, ZJ | 1 |
| Tan, QR | 1 |
| Tong, Y | 1 |
| Li, Q | 1 |
| Kang, WH | 1 |
| Zhen, XC | 1 |
| Post, RM | 34 |
| Kocher, R | 1 |
| Uhde, TW | 17 |
| Rubinow, DR | 6 |
| Ballenger, JC | 8 |
| Gold, PW | 4 |
| Kwamie, Y | 1 |
| Persad, E | 1 |
| Stancer, H | 1 |
| Barker, WA | 1 |
| Eccleston, D | 1 |
| Pickar, D | 1 |
| Naber, D | 1 |
| Bunney, WE | 3 |
| Smith, C | 1 |
| Wolff, EA | 1 |
| Keisling, R | 1 |
| Zorumski, CF | 1 |
| Bakris, GL | 1 |
| Joffe, RT | 9 |
| Roy-Byrne, PP | 3 |
| Udhe, TW | 1 |
| Lewis, HA | 1 |
| Bacher, NM | 1 |
| Reiss, AL | 1 |
| O'Donnell, DJ | 1 |
| Roy-Byrne, P | 1 |
| Baciewicz, G | 1 |
| Yerevanian, BI | 1 |
| Chatterji, DC | 1 |
| Greene, RF | 1 |
| Wehr, TA | 1 |
| Privitera, MR | 1 |
| Greden, JF | 1 |
| Gardner, RW | 1 |
| Ritchie, JC | 1 |
| Carroll, BJ | 1 |
| Parekh, PI | 1 |
| Worthington, K | 1 |
| Campbell, M | 1 |
| Cueva, JE | 1 |
| Bak, TH | 1 |
| Bauer, M | 1 |
| Schaub, RT | 1 |
| Hellweg, R | 1 |
| Reischies, FM | 1 |
| Pisani, F | 2 |
| Fazio, A | 2 |
| Oteri, G | 2 |
| Artesi, C | 1 |
| Xiao, B | 1 |
| Perucca, E | 2 |
| Di Perri, R | 2 |
| Vanelle, JM | 1 |
| Loo, H | 1 |
| Galinowski, A | 1 |
| de Carvalho, W | 1 |
| Bourdel, MC | 1 |
| Brochier, P | 1 |
| Bouvet, O | 1 |
| Brochier, T | 1 |
| Olie, JP | 1 |
| Tohen, M | 2 |
| Castillo, J | 1 |
| Baldessarini, RJ | 2 |
| Zarate, C | 1 |
| Kando, JC | 1 |
| Kramlinger, KG | 3 |
| Phillips, KA | 1 |
| Kubota, T | 1 |
| Ishikura, T | 1 |
| Jibiki, I | 1 |
| Motohashi, N | 1 |
| Kubota, M | 1 |
| Onose, H | 1 |
| Kariya, T | 1 |
| Marangell, LB | 3 |
| George, MS | 5 |
| Bissette, G | 1 |
| Pazzaglia, P | 1 |
| Huggins, T | 2 |
| Guidotti, A | 1 |
| Rubinow, D | 1 |
| Pan, B | 1 |
| Mikalauskas, K | 1 |
| Stuppaeck, CH | 1 |
| Barnas, C | 3 |
| Schwitzer, J | 3 |
| Fleischhacker, WW | 3 |
| Tyrer, SP | 1 |
| Brittlebank, AD | 1 |
| Reus, VI | 1 |
| Doshi, D | 1 |
| Borison, R | 1 |
| Simhandl, C | 1 |
| Denk, E | 1 |
| Thau, K | 1 |
| Greil, W | 2 |
| Ludwig-Mayerhofer, W | 2 |
| Steller, B | 1 |
| Czernik, A | 3 |
| Giedke, H | 1 |
| Müller-Oerlinghausen, B | 2 |
| Osterheider, M | 1 |
| Rudolf, GA | 1 |
| Sauer, H | 3 |
| Tegeler, J | 1 |
| Stuppaeck, C | 2 |
| Wright, S | 1 |
| Young, AW | 1 |
| Hellawell, DJ | 1 |
| Schaff, MR | 1 |
| Fawcett, J | 1 |
| Zajecka, JM | 1 |
| Pardoen, D | 2 |
| Bauwens, F | 2 |
| Tracy, A | 1 |
| Martin, F | 1 |
| Mendlewicz, J | 3 |
| Kröber, HL | 1 |
| Varney, NR | 2 |
| Garvey, MJ | 2 |
| Cook, BL | 1 |
| Campbell, DA | 1 |
| Roberts, RJ | 2 |
| Mas, F | 1 |
| Prichep, LS | 1 |
| Alper, K | 1 |
| Walls, MJ | 1 |
| Bowers, TC | 1 |
| Dilsaver, SC | 1 |
| Swann, AC | 1 |
| Wassermann, EM | 1 |
| Williams, WA | 1 |
| Callahan, A | 1 |
| Basser, P | 1 |
| Hallett, M | 1 |
| Blanco-Jerez, C | 1 |
| Robles, DE | 1 |
| Gilaberte-Asin, I | 1 |
| Blanco, C | 1 |
| Otani, K | 1 |
| Yasui, N | 1 |
| Kaneko, S | 1 |
| Ohkubo, T | 1 |
| Osanai, T | 1 |
| Sugawara, K | 1 |
| Rothschild, AJ | 1 |
| Jenkins, JB | 1 |
| Schroeder, DH | 1 |
| Pazzaglia, PJ | 2 |
| Callahan, AM | 2 |
| Hinton, ML | 1 |
| Chao, J | 1 |
| Leinonen, E | 2 |
| Lepola, U | 1 |
| Koponen, H | 1 |
| Fritze, J | 1 |
| Schneider, B | 1 |
| Maurer, K | 1 |
| Richter, P | 1 |
| Schöchlin, C | 1 |
| von Zerssen, D | 1 |
| Zarate, CA | 1 |
| Baraibar, G | 1 |
| Spear, J | 1 |
| Ranger, M | 1 |
| Herzberg, J | 1 |
| Denicoff, KD | 1 |
| Smith-Jackson, EE | 1 |
| Disney, ER | 1 |
| Ali, SO | 1 |
| Leverich, GS | 3 |
| Mannel, M | 1 |
| Thomas, P | 1 |
| Maron, M | 1 |
| Rascle, C | 1 |
| Cottencin, O | 1 |
| Vaiva, G | 1 |
| Goudemand, M | 1 |
| Kudoh, A | 1 |
| Ishihara, H | 1 |
| Matsuki, A | 1 |
| Dietrich, DE | 1 |
| Emrich, HM | 1 |
| Staner, L | 1 |
| Dramaix, M | 1 |
| Frye, MA | 1 |
| Kimbrell, TA | 1 |
| Cora-Locatelli, G | 1 |
| Luckenbaugh, D | 1 |
| Jamison, KR | 1 |
| Shelton, RC | 1 |
| Rybakowski, JK | 1 |
| Suwalska, A | 1 |
| Chlopocka-Woźniak, M | 1 |
| Romero, AS | 1 |
| Delgado, RG | 1 |
| Peña, MF | 1 |
| Khan, A | 2 |
| Shad, MU | 1 |
| Preskorn, SH | 1 |
| Bottlender, R | 1 |
| Rudolf, D | 1 |
| Strauss, A | 1 |
| Möller, HJ | 1 |
| Szymura-Oleksiak, J | 1 |
| Wyska, E | 1 |
| Wasieczko, A | 1 |
| Roth, L | 1 |
| Bertschy, G | 1 |
| Scott, J | 1 |
| Pope, M | 1 |
| Yamamoto, S | 1 |
| Miyamoto, T | 1 |
| Morita, N | 1 |
| Yasuda, M | 1 |
| Villeneuve, A | 1 |
| De la Fuente, JM | 1 |
| Uehlinger, C | 1 |
| Barrelet, L | 1 |
| Touabi, M | 1 |
| Lambert, M | 1 |
| Fournier, A | 1 |
| Labrecque, J | 1 |
| Coté, MA | 1 |
| Vincent, P | 1 |
| Gertz, HJ | 1 |
| Rybakowski, J | 1 |
| Barklage, NE | 2 |
| Jefferson, JW | 2 |
| Margolis, D | 1 |
| Cullen, M | 1 |
| Mitchell, P | 1 |
| Brodaty, H | 1 |
| Boyce, P | 1 |
| Parker, G | 1 |
| Hickie, I | 1 |
| Wilhelm, K | 1 |
| Lillsunde, P | 1 |
| Laukkanen, V | 1 |
| Ylitalo, P | 1 |
| Bohlken, J | 1 |
| Priebe, S | 1 |
| Signer, SF | 3 |
| Krelina, M | 1 |
| Springer, JA | 1 |
| Silverstone, P | 1 |
| Fahy, T | 1 |
| Schweizer, E | 1 |
| Rickels, K | 1 |
| Case, WG | 1 |
| Greenblatt, DJ | 1 |
| Loonen, AJ | 1 |
| Doorschot, CH | 1 |
| Van Bavel, LP | 1 |
| Groot, B | 1 |
| De Blok, HJ | 1 |
| Krijgsman, LJ | 1 |
| Van Dongen, PH | 1 |
| Jaspers, AA | 1 |
| Vanbrabant, LC | 1 |
| Herman, R | 1 |
| Obarzanek, E | 1 |
| Mikalauskas, KM | 1 |
| Jimerson, DC | 1 |
| Elphick, M | 1 |
| Yang, JD | 1 |
| Cowen, PJ | 1 |
| Delucchi, GA | 1 |
| Rosoff, AS | 1 |
| Altshuler, LL | 1 |
| Hintsche-Kilger, BB | 1 |
| Fengler, JD | 1 |
| Baumgarten, R | 1 |
| Greenspan, D | 1 |
| Schneier, HA | 1 |
| Kahn, D | 1 |
| Miller, C | 1 |
| Brent, DA | 2 |
| Crumrine, PK | 2 |
| Varma, R | 1 |
| Brown, RV | 1 |
| Allan, MJ | 1 |
| Pearson, HJ | 1 |
| Kessler, AJ | 1 |
| McMurray, JS | 1 |
| McCreery, JM | 1 |
| Hunt, HM | 1 |
| Livingston, M | 1 |
| Keitner, GI | 1 |
| Fruzzetti, AE | 1 |
| Miller, IW | 1 |
| Norman, WH | 1 |
| Brown, WA | 1 |
| Arana, GW | 1 |
| Santos, AB | 1 |
| Knax, EP | 1 |
| von Bardeleben, U | 1 |
| Wiedemann, K | 1 |
| Stalla, GK | 1 |
| Müller, OA | 1 |
| Holsboer, F | 1 |
| Reichlin, S | 1 |
| Cookson, JC | 1 |
| Myers, WC | 1 |
| Carrera, F | 1 |
| Lipper, S | 1 |
| Guttmacher, LB | 1 |
| Goldstein, MG | 1 |
| Placidi, GF | 1 |
| Lenzi, A | 1 |
| Lazzerini, F | 1 |
| Cassano, GB | 1 |
| Akiskal, HS | 1 |
| Wetzel, H | 1 |
| Heuser, I | 1 |
| Benkert, O | 1 |
| Barros, HM | 1 |
| Leite, JR | 1 |
| Kobayashi, T | 1 |
| Kishimoto, A | 1 |
| Inagaki, T | 1 |
| Schou, M | 1 |
| Hashimoto, R | 1 |
| Ozaki, N | 1 |
| Ohta, T | 1 |
| Kasahara, Y | 1 |
| Kaneda, N | 1 |
| Nagatsu, T | 1 |
| Roberts, MA | 1 |
| Attah, JR | 1 |
| Cowdry, RW | 2 |
| Gardner, DL | 2 |
| Yassa, R | 1 |
| Iskandar, H | 1 |
| Nastase, C | 1 |
| Camille, Y | 1 |
| Madakasira, S | 1 |
| Minichiello, MD | 1 |
| Ternes, J | 1 |
| Woody, R | 1 |
| Livingston, R | 1 |
| Varma, RR | 1 |
| Allan, M | 1 |
| Allman, C | 1 |
| Tasini, M | 1 |
| Juergens, SM | 1 |
| Milliner, DS | 1 |
| Lee, ME | 1 |
| Russo, M | 1 |
| Trio, R | 1 |
| Pisani, B | 1 |
| Lowy, MT | 1 |
| Meltzer, HY | 1 |
| Schönbeck, G | 1 |
| Langer, G | 1 |
| Benson, DF | 1 |
| Rudnick, FD | 1 |
| Linnoila, M | 1 |
| Schaffer, CB | 1 |
| Mungas, D | 1 |
| Rockwell, E | 1 |
| Prasad, AJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Homeopathic Treatment in Pregnant Women With Overweight and Mental Disorder: a Double Blinded Controlled Clinical Trial[NCT00942097] | Phase 2/Phase 3 | 134 participants (Actual) | Interventional | 2009-08-31 | Completed | ||
| Rapid Acting Transcranial Magnetic Stimulation[NCT04739969] | 100 participants (Anticipated) | Interventional | 2021-06-15 | Recruiting | |||
| Utilizing Changes in Human Brain Connectivity to Establish a Dose-response Relationship Involved in the Therapeutic Actions of Prefrontal Brain Stimulation on Depression Symptoms[NCT04243798] | 100 participants (Anticipated) | Interventional | 2021-06-15 | Recruiting | |||
| Pilot Accelerated Theta Burst Stimulation in Treatment-Resistant Bipolar Depression[NCT03953417] | 30 participants (Anticipated) | Interventional | 2019-07-01 | Active, not recruiting | |||
| Controlled Studies of Repetitive Transcranial Magnetic Stimulation (rTMS) in Chronic Posttraumatic Stress Disorder (PTSD)[NCT00001657] | 30 participants | Observational | 1997-06-30 | Completed | |||
| Personalized Therapeutic Neuromodulation for Anhedonic Depression[NCT05144789] | 100 participants (Anticipated) | Interventional | 2022-05-31 | Recruiting | |||
| Modulating Probabilities: Prediction, Assessment, and Treatment of Acute Mood Depressive Episode in Borderline Personality Disorder With rTMS[NCT04870255] | 45 participants (Anticipated) | Interventional | 2021-07-20 | Recruiting | |||
| Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression (SAINT-TRD)[NCT03240692] | 23 participants (Actual) | Interventional | 2017-05-01 | Completed | |||
| Establishing Functional Biomarkers for Spaced Theta-Burst Stimulation[NCT03687892] | 37 participants (Actual) | Interventional | 2019-04-01 | Terminated (stopped due to Change in study personnel.) | |||
| Noninvasive Brain Stimulation Training to Help Recover Brain-related Symptoms[NCT03228472] | 100 participants (Anticipated) | Interventional | 2017-11-22 | Recruiting | |||
| Individualized Neuroimaging Biomarkers for Predicting rTMS Response in OCD[NCT04286126] | 180 participants (Anticipated) | Interventional | 2021-01-15 | Recruiting | |||
| Therapeutic Efficacy of Cerebellar Repetitive Transcranial Magnetic Stimulation in Patients With Schizophrenia[NCT01551979] | 22 participants (Actual) | Interventional | 2012-02-29 | Completed | |||
| Repetitive Transcranial Magnetic Stimulation (rTMS) for Motor and Mood Symptoms of Parkinson's Disease (MASTER-PD), a Multicenter Clinical Trial[NCT01080794] | 61 participants (Actual) | Interventional | 2010-05-31 | Completed | |||
| The Effects of Stanford Accelerated Intelligent Neuromodulation Therapy on Explicit and Implicit Suicidal Cognition[NCT03693105] | 100 participants (Anticipated) | Interventional | 2021-11-07 | Enrolling by invitation | |||
| Accelerated Intermittent Theta Burst Stimulation for Depressive Symptoms[NCT03601117] | 23 participants (Actual) | Interventional | 2018-07-01 | Completed | |||
| Accelerated Intermittent Theta-burst Stimulation for Treatment of Preoperative Depression to Reduce Conversion of Acute to Chronic Opioid Use Following Arthroplasty[NCT04195308] | 0 participants (Actual) | Interventional | 2024-06-30 | Withdrawn (stopped due to Logistical constraints) | |||
| Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression (SAINT-TRD)[NCT03068715] | 30 participants (Actual) | Interventional | 2017-03-20 | Completed | |||
| Rapid Acting Transcranial Magnetic Stimulation for Suicide Ideation in Depression[NCT05100004] | 100 participants (Anticipated) | Interventional | 2021-11-07 | Recruiting | |||
| Accelerated Theta Burst in Treatment-Resistant Depression: A Dose Finding and Biomarker Study[NCT03680781] | 90 participants (Anticipated) | Interventional | 2018-04-13 | Enrolling by invitation | |||
| Repetitive Transcranial Magnetic Stimulation (rTMS) for Orthopaedic Trauma Patients[NCT03924024] | 0 participants (Actual) | Interventional | 2019-08-01 | Withdrawn (stopped due to We never started the study due to logistical limitations.) | |||
| Accelerated Intermittent Theta-Burst Stimulation (aiTBS) in Treatment-Resistant Depression of Bipolar II Disorder[NCT05849402] | 60 participants (Anticipated) | Interventional | 2022-12-20 | Recruiting | |||
| Pilot Evaluation of Levetiracetam (Keppra® (Registered Trademark)) in Bipolar Illness[NCT00015769] | Phase 2 | 30 participants | Interventional | 2001-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
A ten item diagnostic questionnaire used to measure the severity of depressive symptoms in patients with mood disorders. Scale range - 0 to 60 with higher score indicative of greater depressive symptomology. (NCT03240692)
Timeframe: Pre-treatment and 1-month post treatment.
| Intervention | Percentage of change in score (Mean) |
|---|---|
| Accelerated Theta Burst Treatment | -67.07 |
The Hopkins Verbal Learning Test - Revised (HVLT-DR). Score range 0 to 72, higher score indicates better verbal learning. The Brief Visuospatial Memory Test - Revised (BVMT-DR). Score range 0 to 84, higher score indicates better visuospatial memory. Digit Span test and various tests from the Delis Kaplan Executive Function System (DKEFS) will be used to assess possible cognitive side-effects. Score range 0-36, higher score indicates better executive functions. (NCT03240692)
Timeframe: Pre-treatment, immediately post-treatment (on day 5) and 4 weeks post-treatment
| Intervention | score on a scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| HVLT-DR_Pre-treatment | HVLT-DR_ immediately post-treatment | HVLT-DR_Week 4 | BVMT-DR_Pre-treatment | BVMT-DR_ immediately post-treatment | BVMT-DR_Week 4 | DKEFS_Pre-treatment | DKEFS_ immediately post-treatment | DKEFS_Week 4 | |
| Accelerated Theta Burst Treatment | 48.81 | 48.18 | 49.77 | 51.06 | 54.35 | 56.23 | 17.35 | 19.06 | 19.15 |
"Within subject changes in resting state functional connectivity of subgenual anterior cingulate cortex (sgACC) to default mode network (DMN). frontal (f)DMN (medial prefrontal cortex), median (m)DMN (posterior cingulate cortex and precuneus), left (l)DMN (left angular gyrus), right (r)DMN (right angular gyrus).~T-statistic (T-score): ratio of departure of estimated value from its hypothesized value to its standard error used in a t-test to determine whether to support or reject the null hypothesis. A T-score of ≥ 2.11 or ≤ -2.11 would be considered a statistically significant change if the accompanying p-value (subject to false discovery rate correction of multiple comparisons) was ≤ 0.05. Positive T-score = increased connectivity, negative T-score = decreased connectivity. No established reference range or clinically meaningful threshold exists for this patient population. Higher connectivity between all DMN nodes to sgACC has been found in depressed vs healthy population." (NCT03240692)
Timeframe: Pre-treatment to immediately post treatment (on day 5).
| Intervention | T-score (Number) | |||
|---|---|---|---|---|
| sgACC-fDMN | sgACC-mDMN | sgACC-lDMN | sgACC-rDMN | |
| Accelerated Theta Burst Treatment | -2.335 | -3.027 | -2.106 | -2.660 |
A 21 item Self-report measure of depressive symptoms. Scale range - 0 to 63 with higher score indicative of greater depressive symptomology. Additional collection time points were pre-specified; only those time points for which data were collected are reported. (NCT03240692)
Timeframe: Pretreatment to immediately post-treatment (on day 5) and 2 weeks, 4 weeks, 6 weeks and 8 weeks post treatment.
| Intervention | Percentage of change in score. (Mean) | ||||
|---|---|---|---|---|---|
| Immediately post-treatment | Week 2 | Week 4 | Week 6 | Week 8 | |
| Accelerated Theta Burst Treatment | -84.89 | -65.32 | -54.84 | -90.74 | -100 |
A suicidal ideation rating scale created by researchers at Columbia University. The score was calculated by summing the answers to 5 questions. Score range - 0 to 5. Higher score indicate higher suicidal ideation. (NCT03240692)
Timeframe: Pre-treatment to immediately post-treatment (on day 5) and 4 weeks post-treatment
| Intervention | Percentage of change in score (Mean) | |
|---|---|---|
| Immediately post-treatment | 4 weeks post-treatment | |
| Accelerated Theta Burst Treatment | -100 | -100 |
A provider administered questionnaire used to assess remission and recovery from depression. Scale range - 0 to 52 with higher score indicative of greater depressive symptomology. Additional collection time points were pre-specified; only those time points for which data were collected are reported. (NCT03240692)
Timeframe: Pre-treatment to immediately post-treatment (on day 5) and 2 weeks, 4 weeks, 6 weeks and 8 weeks post-treatment
| Intervention | Percentage of change in score (Mean) | ||||
|---|---|---|---|---|---|
| immediately post-treatment | Week 2 | Week 4 | Week 6 | Week 8 | |
| Accelerated Theta Burst Treatment | -81.12 | -74.58 | -68.25 | -88.89 | -93.52 |
A 6 item questionnaire used to score the severity of depression. Scale range - 0 to 22 with higher score indicative of greater depressive symptomology. Additional collection time points were pre-specified; only those time points for which data were collected are reported. (NCT03240692)
Timeframe: Pre-treatment to immediately post-treatment (on day 5) and 2 weeks,4 weeks and 6 weeks post-treatment
| Intervention | Percentage of change in score (Mean) | |||
|---|---|---|---|---|
| immediately post-treatment | Week 2 | Week 4 | Week 6 | |
| Accelerated Theta Burst Treatment | -81.96 | -71.94 | -65.54 | -87.5 |
A ten item diagnostic questionnaire used to measure the severity of depressive symptoms in patients with mood disorders. Scale range - 0 to 60 with higher score indicative of greater depressive symptomology. Additional collection time points were pre-specified; only those time points for which data were collected are reported. (NCT03240692)
Timeframe: Pre-treatment to immediately post treatment (on day 5) and 2 weeks, 4 weeks and 8 weeks post-treatment
| Intervention | Percentage of change in score. (Mean) | |||
|---|---|---|---|---|
| immediately post treatment | Week 2 | Week 4 | Week 8 | |
| Accelerated Theta Burst Treatment | -85.06 | -78.17 | -67.07 | -96.30 |
The Calgary Depression Scale for Schizophrenia is a 9-item scale that assesses depressive symptoms in patients with schizophrenia. Each item is rated separately and ratings range from 0 to 3. Higher values represent more severe depressive symptoms: 0 indicates an absent symptom and 3 indicates a severe symptom. The overall Calgary Depression Scale score is computed by summing each item. The total Calgary Depression Scale score ranges from 0 to 27, with higher values representing more severe depression in patients with schizophrenia. Change from baseline on the Calgary Depression Scale can range from -27 to +27, with negative values representing an improvement in depressive symptoms and positive values representing worsening depressive symptom severity. Depression was assessed at baseline, after 5 days of treatment, 1 week post treatment, and 3 weeks post treatment. (NCT01551979)
Timeframe: Before treatment (baseline), last day of treatment (after 5 days of treatment), 1 and 3 weeks post treatment
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| 5 days of treatment - baseline | 1 week post treatment - baseline | 3 week post treatment - baseline | |
| Active rTMS | -2.6 | -2.7 | -2.25 |
| Sham rTMS | -1.167 | -1.833 | 0.8 |
Treatment response was evaluated with the Clinical Global Impressions (CGI) Scale, which is comprised of two companion one-item measures that use 7-point scales to evaluate severity of psychopathology and improvement from the initiation of treatment; each component is rated separately and the CGI does not yield a global score. The CGI Severity of Illness is a 7-point subscale in which a clinician rates the severity of the patient's illness at the time of assessment. Ratings range from 1 to 7 and higher values represent more severe psychopathology: 1 indicates a normal and not at all ill patient and 7 indicates among the most extremely ill patients. Change from baseline on the CGI Severity of Illness subscale can range from -6 to +6, with negative values representing an improvement in psychopathology and positive values representing worsening psychopathology. Severity of Illness was assessed at baseline, after 5 days of treatment, 1 week post treatment, and 3 weeks post treatment. (NCT01551979)
Timeframe: Before treatment (baseline), last day of treatment (after 5 days of treatment), 1 and 3 weeks post treatment
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| 5 days of treatment - baseline | 1 week post treatment - baseline | 3 week post treatment - baseline | |
| Active rTMS | -0.3 | -0.4 | -0.5 |
| Sham rTMS | -0.286 | -0.5 | -0.2 |
Therapeutic efficacy was evaluated with the Positive and Negative Syndrome Scale (PANSS) General Subscale, a 16 item subscale measuring the presence/absence and severity of general psychopathology of schizophrenia. The minimum score is 16 and the maximum score is 112, with higher values representing greater psychopathology severity. Change from baseline on the PANSS General Subscale can range from -96 to +96; negative values represent an improvement in symptom severity, and positive values represent worsening symptom severity. Therapeutic efficacy was assessed at baseline, after 5 days of treatment, 1 week post treatment, and 3 weeks post treatment. (NCT01551979)
Timeframe: Before treatment (baseline), last day of treatment (after 5 days of treatment), 1 and 3 weeks post treatment
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| 5 days of treatment - baseline | 1 week post treatment - baseline | 3 week post treatment - baseline | |
| Active rTMS | -3.1 | -8.222 | -7.375 |
| Sham rTMS | -2.714 | -2 | 0 |
Therapeutic efficacy was evaluated with the Positive and Negative Syndrome Scale (PANSS) Negative Subscale, a 7 item subscale measuring the presence/absence and severity of negative symptoms of schizophrenia. The minimum score is 7 and the maximum score is 49, with higher values representing greater symptom severity. Change from baseline on the PANSS Negative Subscale can range from -42 to +42; negative values represent an improvement in symptom severity, and positive values represent worsening symptom severity. Therapeutic efficacy was assessed at baseline, after 5 days of treatment, 1 week post treatment, and 3 weeks post treatment. (NCT01551979)
Timeframe: Before treatment (baseline), last day of treatment (after 5 days of treatment), 1 and 3 weeks post treatment
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| 5 days of treatment - baseline | 1 week post treatment - baseline | 3 week post treatment - baseline | |
| Active rTMS | -1 | -3.889 | -3.5 |
| Sham rTMS | -1.571 | -1.667 | -0.2 |
Therapeutic efficacy was evaluated with the Positive and Negative Syndrome Scale (PANSS) Positive Subscale, a 7 item subscale measuring the presence/absence and severity of positive symptoms of schizophrenia. The minimum score is 7 and the maximum score is 49, with higher values representing greater symptom severity. Change from baseline on the PANSS Positive Subscale can range from -42 to +42; negative values represent an improvement in symptom severity, and positive values represent worsening symptom severity. Therapeutic efficacy was assessed at baseline, after 5 days of treatment, 1 week post treatment, and 3 weeks post treatment. (NCT01551979)
Timeframe: Before treatment (baseline), last day of treatment (after 5 days of treatment), 1 and 3 weeks post treatment
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| 5 days of treatment - baseline | 1 week post treatment - baseline | 3 week post treatment - baseline | |
| Active rTMS | -2.4 | -5.889 | -5 |
| Sham rTMS | -1.857 | -3.667 | -3 |
Treatment response was evaluated with the Clinical Global Impressions (CGI) Scale, which is comprised of two companion one-item measures that use 7-point scales to evaluate severity of psychopathology and improvement from the initiation of treatment; each component is rated separately and the CGI does not yield a global score. The CGI Global Improvement is a 7-point subscale in which a clinician assesses how much a patient's illness has changed compared to baseline. Ratings range from 1 to 7, with 1 indicating very much improved and 7 indicating very much worse. Change from baseline on the CGI Global Improvement subscale can range from -6 to +6, with negative values representing an improvement in psychopathology and positive values representing worsening psychopathology. Global Improvement was assessed after 5 days of treatment, 1 week post treatment, and 3 weeks post treatment. (NCT01551979)
Timeframe: Last day of treatment (after 5 days of treatment), 1 and 3 weeks post treatment
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| 5 days of treatment | 1 week post treatment | 3 week post treatment | |
| Active rTMS | 3.6 | 3.3 | 3.375 |
| Sham rTMS | 3.429 | 4 | 3.8 |
To establish the safety and tolerability of rTMS in Parkinson's Disease. (NCT01080794)
Timeframe: Baseline through Month 6
| Intervention | incidents of an adverse event (Number) |
|---|---|
| Double rTMS | 18 |
| M1 Active rTMS + DLPFC Sham rTMS | 14 |
| DLPFC Active rTMS + M1 Sham rTMS | 1 |
| Double Sham rTMS | 1 |
To evaluate apathy in Parkinson's Disease. The AES mean scores were reported for each group at each time point. The AES Score Range is 0-42, where higher the score indicates greater severity of the apathy symptoms. (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline (Pre-Treatment) | Week 1 Post Treatment | Month 1 Post Treatment | Month 3 Post Treatment | Month 6 Post Treatment | |
| DLPFC Active rTMS + M1 Sham rTMS | 18.7 | 18.1 | 19.0 | 19.3 | 15.8 |
| Double rTMS | 15.6 | 16.2 | 17 | 16.9 | 17.8 |
| Double Sham rTMS | 16.3 | 15.5 | 15.0 | 16.1 | 16.2 |
| M1 Active rTMS + DLPFC Sham rTMS | 15.9 | 16.9 | 14.6 | 15.1 | 12.4 |
To assess mood symptoms in Parkinson's Disease. The BDI-II mean scores were reported for each group at each time point. The BDI-II Score Range is 0 - 63, where higher the score indicates greater severity of the mood symptoms. (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline (Pre-Treatment) | Week 1 Post Treatment | Month 1 Post Treatment | Month 3 Post Treatment | Month 6 Post Treatment | |
| DLPFC Active rTMS + M1 Sham rTMS | 21.7 | 18.2 | 20.2 | 19.0 | 15.7 |
| Double rTMS | 23.2 | 20.7 | 16.4 | 17.9 | 20.1 |
| Double Sham rTMS | 18.8 | 13.7 | 13.1 | 14.7 | 16.8 |
| M1 Active rTMS + DLPFC Sham rTMS | 18.5 | 16.5 | 16.7 | 19.1 | 16.3 |
To evaluate anxiety in Parkinson's Disease. The CAS mean scores were reported for each group at each time point. The CAS Score Range is 0 - 100, where higher the score indicates greater severity of the anxiety symptoms. (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline (Pre-Treatment) | Week 1 Post Treatment | Month 1 Post Treatment | Month 3 Post Treatment | Month 6 Post Treatment | |
| DLPFC Active rTMS + M1 Sham rTMS | 33.4 | 27.6 | 30.8 | 31.4 | 24.8 |
| Double rTMS | 36.3 | 34.2 | 31.7 | 33.1 | 33.4 |
| Double Sham rTMS | 37.5 | 32.4 | 28.2 | 28.5 | 35.0 |
| M1 Active rTMS + DLPFC Sham rTMS | 34.3 | 31.0 | 30.8 | 27.3 | 28.1 |
To assess symptom severity and treatment response in Parkinson's Disease. The CGI mean scores were reported for each group at each time point. The CGI Score Range is 1 - 8, where higher the score indicates greater severity of illness or worsening of illness. (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.
| Intervention | units on a scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline (Pre-Treatment): Severity | Week 1 Post Treatment: Severity | Week 1 Post Treatment: Improvement | Month 1 Post Treatment: Severity | Month 1 Post Treatment: Improvement | Month 3 Post Treatment: Severity | Month 3 Post Treatment: Improvement | Month 6 Post Treatment: Severity | Month 6 Post Treatment: Improvement | |
| DLPFC Active rTMS + M1 Sham rTMS | 4.3 | 4.7 | 3.5 | 4.4 | 3.7 | 4.4 | 3.6 | 4.3 | 3.7 |
| Double rTMS | 4.9 | 4.8 | 3.6 | 4.4 | 3.5 | 4.6 | 3.7 | 4.2 | 3.5 |
| Double Sham rTMS | 3.6 | 3.9 | 3.0 | 4.1 | 3.5 | 4.4 | 3.6 | 4.6 | 3.4 |
| M1 Active rTMS + DLPFC Sham rTMS | 4.7 | 4.9 | 3.5 | 4.8 | 3.8 | 3.8 | 3.4 | 5.0 | 4.2 |
"To evaluate the depressive mood symptoms in PD.~The HAM-D mean scores were reported for each group at each time point. The HAM-D Score Range is 0 - 56, where higher the score indicates greater severity of depressive mood symptoms." (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline (Pre-Treatment) | Week 1 Post-Treatment | Month 1 Post-Treatment | Month 3 Post-Treatment | Month 6 Post-Treatment | |
| DLPFC Active rTMS + M1 Sham rTMS | 13.8 | 9.4 | 12.4 | 10.4 | 10.4 |
| Double rTMS | 15.2 | 11.3 | 10.6 | 10.7 | 10.4 |
| Double Sham rTMS | 14.1 | 9.3 | 8.0 | 11.1 | 10.4 |
| M1 Active rTMS + DLPFC Sham rTMS | 16.7 | 11.2 | 10.1 | 10.1 | 8.6 |
To screen and follow cognitive function in Parkinson's Disease. The MoCA mean scores were reported for each group at each time point. The MoCA Score Range is 0 - 30, where 26-30 indicates normal cognition. (NCT01080794)
Timeframe: pre-treatment; 0,1,3, and 6 months post-treatment
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline (Pre-Treatment) | Week 1 Post Treatment | Month 1 Post Treatment | Month 3 Post Treatment | Month 6 Post Treatment | |
| DLPFC Active rTMS + M1 Sham rTMS | 27.3 | 26.3 | 26.8 | 26.7 | 26.6 |
| Double rTMS | 28.2 | 26.8 | 28.8 | 26.5 | 28.0 |
| Double Sham rTMS | 26.2 | 27.8 | 28.7 | 24.9 | 28.0 |
| M1 Active rTMS + DLPFC Sham rTMS | 26.6 | 27.1 | 27.2 | 25.3 | 27.9 |
"To evaluate the motor symptoms in Parkinson's Disease.~The UPDRS-III mean scores were reported for each group at each time point. The UPDRS-III Score Range is 0 - 56, where higher the score indicates greater severity of the motor symptoms." (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline (Pre-Treatment) | Week 1 Post-Treatment | Month 1 Post-Treatment | Month 3 Post-Treatment | Month 6 Post-Treatment | |
| DLPFC Active rTMS + M1 Sham rTMS | 32.8 | 30.3 | 29.3 | 31.5 | 28.8 |
| Double rTMS | 32.3 | 31.2 | 30.1 | 29.6 | 30.5 |
| Double Sham rTMS | 28.9 | 28.2 | 28.6 | 28.6 | 29.0 |
| M1 Active rTMS + DLPFC Sham rTMS | 33.1 | 27.4 | 28.1 | 33.2 | 30.6 |
To assess the quality of life (QOL) in Parkinson's Disease. The PDQ-39 mean scores were reported for each group at each time point. The PDQ-39 Score Range is 0 - 156, where higher the score indicates greater impact on quality of life. (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline (Pre-Treatment) | Week 1 Post Treatment | Month 1 Post Treatment | Month 3 Post Treatment | Month 6 Post Treatment | |
| DLPFC Active rTMS + M1 Sham rTMS | 51.9 | 46.8 | 49.4 | 49.4 | 49 |
| Double rTMS | 57.6 | 51.2 | 49.9 | 51.7 | 50.5 |
| Double Sham rTMS | 55.5 | 43.1 | 40.9 | 43.1 | 47.5 |
| M1 Active rTMS + DLPFC Sham rTMS | 61.5 | 60.7 | 56.8 | 53.1 | 48.3 |
"To assess apathy, cognition, depression, activities of daily living (ADL), quality of life (QOL), and motor symptoms in Parkinson's Disease.~The UPDRS I, II, IV total mean scores were reported for each group at each time point. The UPDRS I, II, IV scores were added together for each patient, with a total score range of 0 - 91, where higher the score indicates greater severity of the symptoms." (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline (Pre-Treatment) | Week 1 Post Treatment | Month 1 Post Treatment | Month 3 Post Treatment | Month 6 Post Treatment | |
| DLPFC Active rTMS + M1 Sham rTMS | 21.5 | 19.3 | 19.9 | 18.9 | 20.2 |
| Double rTMS | 25.4 | 23.3 | 21.8 | 21.1 | 23.8 |
| Double Sham rTMS | 19.6 | 15.5 | 16.5 | 16.9 | 18.8 |
| M1 Active rTMS + DLPFC Sham rTMS | 26.1 | 23.2 | 23.0 | 23.2 | 22.7 |
"The Beck Depression Inventory (BDI-II) is a 21-item, self-report rating inventory that measures characteristic attitudes and symptoms of depression. BDI-II items are rated on a 4-point scale ranging from 0 to 3 based on severity of each item. The maximum total score is 63.~Scores: 0-13= minimal depression, 14-19=mild depression, 20-28=moderate depression, 29-63=severe depression.~Data are presented as a raw score point change." (NCT03601117)
Timeframe: After all stimulation sessions have been completed (approximately 48 hours after the final session)
| Intervention | score on a scale (Mean) |
|---|---|
| Dorsolateral Prefrontal Cortex | 18.88 |
| Anterior Cingulate Cortex (ACC) | 6 |
"Clinical assessment measuring depressive symptoms. Scores range from 0-24 with scores >5 indicating clinical levels of depressive symptoms (higher scores are more symptomatic).~Data are presented as a raw score point change." (NCT03601117)
Timeframe: After all stimulation sessions have been completed (approximately 48 hours after the final session)
| Intervention | score on a scale (Mean) |
|---|---|
| Dorsolateral Prefrontal Cortex | 10 |
| Anterior Cingulate Cortex (ACC) | 1 |
"Measure presence of any change in heart rate variability.~Data is reported as a ratio of low frequency (LF) and high frequency (HF) (LF/HF FFT).~FFT: fast Fourier transform." (NCT03601117)
Timeframe: After all stimulation sessions have been completed (approximately 48 hours after the final session)
| Intervention | LF/HF FFT ratio (Mean) |
|---|---|
| Dorsolateral Prefrontal Cortex | -1.88 |
"Immediate Mood Scaler (IMS) is a newly developed, iPad-deliverable 12-item self-report tool designed to capture current mood states with overall score, and depression and anxiety subscales. Individual item scores range from 1-7, with a total overall score range from 12-84.~Data are presented as a raw score point change in depression subscale score. The depression subscale scores range from 7-49 (higher score indicating worse depression)." (NCT03601117)
Timeframe: After all stimulation sessions have been completed (approximately 48 hours after the final session)
| Intervention | score on a scale (Mean) |
|---|---|
| Dorsolateral Prefrontal Cortex | 11 |
| Anterior Cingulate Cortex (ACC) | -6 |
"A 10-item clinician-administered scale, designed to be particularly sensitive to antidepressant treatment effects in patients with major depression. Severity gradations for the MADRS have been proposed: 9-17 = mild depression, 18-34 = moderate depression, and ≥ 35 = severe depression. Scores range from 0-60 (higher scores are more symptomatic).~Response is defined as a 50% reduction or greater in MADRS score compared to baseline. Remission is defined as a MADRS score of <10.~Data are presented as a raw score point change." (NCT03601117)
Timeframe: After all stimulation sessions have been completed (approximately 48 hours after the final session)
| Intervention | score on a scale (Mean) |
|---|---|
| Dorsolateral Prefrontal Cortex (L-DLPFC) | 26.59 |
| Anterior Cingulate Cortex (ACC) | 16 |
"Self-report, 20 item scale to determine patient's insomnia level.~Each question can be scored between 0-3. 0=not bothered at all~slightly bothered moderately bothered severely bothered~Total score is calculated by adding up all questions (i.e. Q1+Q2+...Q20). One missing item is allowed, pro-rate if missing one item....i.e. (sum/count)*20.~Minimum Score = 0 (good); Maximum Score = 60 (bad).~Data are presented as a raw score point change." (NCT03601117)
Timeframe: After all stimulation sessions have been completed (approximately 48 hours after the final session)
| Intervention | score on a scale (Mean) |
|---|---|
| Dorsolateral Prefrontal Cortex | 16.23 |
| Anterior Cingulate Cortex (ACC) | 24 |
"Self-report measure of depressive symptoms. The questionnaire consists of 16 questions. Each question can score between 0 to 4 points.~Severity of depression is determined as follows: 0=None, 1=Mild, 2=Moderate, 3=Severe, 4=Very Severe.~Total scores range from 0-27. Total scores: 0-5= no depression, 6-10= mild depression, 11-15= moderate depression, 16-20= severe depression, 21-27= very severe depression.~The total score is obtained by adding the scores for each of the nine symptom domains of the DSM-IV MDD criteria: depressed mood, loss of interest or pleasure, concentration/decision making, self-outlook, suicidal ideation, energy/fatigability, sleep, weight/appetite change, and psychomotor changes (Rush et al. 2003).~Data are presented as a raw score point change." (NCT03601117)
Timeframe: After all stimulation sessions have been completed (approximately 48 hours after the final session)
| Intervention | score on a scale (Mean) |
|---|---|
| Dorsolateral Prefrontal Cortex | 11.29 |
| Anterior Cingulate Cortex (ACC) | 6 |
"19-item clinician administered assessment to measure the intensity, pervasiveness, and characteristics of suicidal ideation in adults.~Scores range from 0-38. Higher scores indicate more suicidality.~Data are presented as a raw score point change." (NCT03601117)
Timeframe: After all stimulation sessions have been completed (approximately 48 hours after the final session)
| Intervention | score on a scale (Mean) |
|---|---|
| Dorsolateral Prefrontal Cortex | 9.82 |
| Anterior Cingulate Cortex | 0 |
"15-item self-report questionnaire where each item is scored from very poor=1 to very good=5.~The scoring of the Q-LES-Q-SF involves summing only the first 14 items to yield a raw total score.~The last two items are not included in the total score but are stand-alone items.~The raw total score ranges from 14 (min) to 70 (max)." (NCT03601117)
Timeframe: After all stimulation sessions have been completed (approximately 48 hours after the final session)
| Intervention | score on a scale (Mean) |
|---|---|
| Dorsolateral Prefrontal Cortex | 12.36 |
| Anterior Cingulate Cortex (ACC) | 5 |
"The Young Mania Rating Scale (YMRS) is one of the most frequently utilized rating scales to assess manic symptoms. The scale has 11 items and is based on the patient's subjective report of his or her clinical condition.~There are four items that are graded on a 0 to 8 scale (irritability, speech, thought content, and disruptive/aggressive behavior), while the remaining seven items are graded on a 0 to 4 scale. These four items are given twice the weight of the others to compensate for poor cooperation from severely ill patients.~Typical YMRS baseline scores can vary a lot. They depend on the patients' clinical features such as mania (YMRS = 12), depression (YMRS = 3), or euthymia (YMRS = 2).~Data are presented as a raw score point change." (NCT03601117)
Timeframe: After all stimulation sessions have been completed (approximately 48 hours after the final session)
| Intervention | score on a scale (Mean) |
|---|---|
| Dorsolateral Prefrontal Cortex | .06 |
| Anterior Cingulate Cortex (ACC) | 0 |
Heart rate variability measures will be compared pre-treatment and 1-month post-treatment. (NCT03068715)
Timeframe: Pretreatment to 1-month post-treatment
| Intervention | SDNN in milliseconds (Mean) |
|---|---|
| Active TBS-DLPFC | 46.609 |
| Sham TBS-DLPFC | -26.670 |
Heart rate variability measures will be compared pre-treatment and immediately post-treatment. (NCT03068715)
Timeframe: Pretreatment to immediate post-treatment (day 8).
| Intervention | SDNN in milliseconds (Mean) |
|---|---|
| Active TBS-DLPFC | 16.226 |
| Sham TBS-DLPFC | -31.159 |
A ten item diagnostic questionnaire used to measure the severity of depressive episodes in patients with mood disorders.The MADRS has an overall score range from 0-60, with higher scores corresponding to higher levels of depression. (NCT03068715)
Timeframe: Pretreatment (baseline), 1-month post-treatment
| Intervention | percent change in MADRS score (Mean) |
|---|---|
| Active TBS-DLPFC | -53 |
| Sham TBS-DLPFC | -11 |
"The Hamilton Depression Rating Scale (HDRS, also known as Ham-D) is the most widely used clinician-administered depression assessment scale.~The Ham-17 version consists of 17 items assessing for: mood, guilt, general somatic symptoms, work and activities, anxiety and slowness of thought and speech. Each item is scored on a scale of 0 to 4, except for the somatic, sleep and insight items which are scored 0 to 2. On the HAM-17 there can be a total score of 22. Higher scores represent higher depression severity." (NCT03068715)
Timeframe: Pre-treatment (baseline) to immediately post-treatment (day 8).
| Intervention | percent change in score (Mean) |
|---|---|
| Active TBS-DLPFC | -59 |
| Sham TBS-DLPFC | -20 |
A provider administered questionnaire used to assess remission and recovery from depression. The HAMD-17 is a 17-item questionnaire to assess depression severity. Each item is scored from 0-4, with higher scores representing increasing depression severity. (NCT03068715)
Timeframe: pre-treatment (baseline) to 1-month post-treatment
| Intervention | percent change in HAM-17 score (Mean) |
|---|---|
| Active TBS-DLPFC | -52 |
| Sham TBS-DLPFC | -12 |
We will assess functional connectivity as seen on resting state fMRI, between the subcallosal cingulate to the default mode network and within the default mode network. We report below, changes of functional connectivity (Fisher's Z score of Pearson correlation coefficient for each pair of ROIs) from post-treatment(1m) to baseline. (NCT03068715)
Timeframe: Pretreatment (baseline) to 1-month post-treatment
| Intervention | Z-score (Mean) | |
|---|---|---|
| lsgACC_lDMN | lDMN_rDMN | |
| Active TBS-DLPFC | 0.090 | -0.039 |
| Sham TBS-DLPFC | -0.163 | -0.056 |
We quantified the functional connectivity change between the subcallosal cingulate to the default mode network and within the default mode network using baseline and immediate post-treatment MRI scans. We report below, changes of functional connectivity (Fisher's Z score of Pearson correlation coefficient for each pair of ROIs) from immediately post-treatment (day 8) to baseline. (NCT03068715)
Timeframe: Pretreatment (baseline) to immediately post-treatment (day 8).
| Intervention | Z-score (Mean) | |
|---|---|---|
| lsgACC_lDMN | lDMN_rDMN | |
| Active TBS-DLPFC | 0.071 | -0.069 |
| Sham TBS-DLPFC | 0.025 | 0.117 |
The Columbia-Suicide Severity Rating Scale (C-SSRS) is a questionnaire used for suicide assessment developed by multiple institutions including Columbia University. Participants were asked a series of 6 yes or no questions. Yes answers indicate more suicidal ideation. Here we report a count of participants with an increase, decrease or no change in suicidal ideation. (NCT03068715)
Timeframe: Pretreatment (baseline) to immediately post-treatment (day 8).
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Increased | Decreased | No Change | |
| Active TBS-DLPFC | 0 | 6 | 2 |
| Sham TBS-DLPFC | 0 | 1 | 5 |
"The Hamilton Depression Rating Scale (HDRS, also known as Ham-D) is the most widely used clinician-administered depression assessment scale.~The Ham-6 version consists of 6 items assessing for: mood, guilt, general somatic symptoms, work and activities, anxiety and slowness of thought and speech). Each item is scored on a scale of 0 to 4, except for the somatic symptoms item, which is scored 0 to 2. On the HAM-6 there can be a total score of 22. Higher scores represent higher depression severity. Here, we report a count of participants with an overall increase, decrease or no change in total HAM-6 score.~Participants with an increase in total score (row 3) would signify a worse outcome than participants with a decrease in total score." (NCT03068715)
Timeframe: Baseline (pre-treatment) and at 1-month post-treatment
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Decreased | No Change | Increased | |
| Active TBS-DLPFC | 8 | 2 | 1 |
| Sham TBS-DLPFC | 3 | 6 | 1 |
22 reviews available for carbamazepine and Depression, Endogenous
| Article | Year |
|---|---|
[Pharmacogenetics in psychiatry: state of the art].
Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Asian People; ATP Bin | 2018 |
Perinatal depression: treatment options and dilemmas.
Topics: Anticonvulsants; Antimanic Agents; Bipolar Disorder; Carbamazepine; Case-Control Studies; Cyclohexan | 2008 |
[Mood stabilizers--past, present and future].
Topics: Affect; Antimanic Agents; Bipolar Disorder; Calcium; Carbamazepine; Depressive Disorder; gamma-Amino | 2008 |
Pharmacologic treatments for pediatric bipolar disorder: a review and meta-analysis.
Topics: Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivi | 2011 |
Newer anticonvulsants in the treatment of bipolar disorder.
Topics: Acetates; Amines; Anticonvulsants; Bipolar Disorder; Carbamazepine; Cyclohexanecarboxylic Acids; Dep | 2004 |
A review of the evidence for carbamazepine and oxcarbazepine in the treatment of bipolar disorder.
Topics: Acute Disease; Anticonvulsants; Bipolar Disorder; Carbamazepine; Controlled Clinical Trials as Topic | 2004 |
Antiepileptic drugs in mood-disordered patients.
Topics: Anticonvulsants; Bipolar Disorder; Carbamazepine; Depressive Disorder; Humans; Lamotrigine; Treatmen | 2005 |
Anticonvulsant drug therapies.
Topics: Amines; Anticonvulsants; Bipolar Disorder; Carbamazepine; Cyclohexanecarboxylic Acids; Depressive Di | 2005 |
The role of mood stabilisers in the treatment of the depressive facet of bipolar disorders.
Topics: Affective Symptoms; Animals; Antimanic Agents; Bipolar Disorder; Carbamazepine; Depressive Disorder; | 2007 |
[Effects of antiepileptic drugs on mood of people with epilepsy].
Topics: Affect; Anticonvulsants; Antidepressive Agents; Carbamazepine; Depressive Disorder; Epilepsy; Fructo | 2007 |
Treatment of mood disorders with antiepileptic medications: clinical and theoretical implications.
Topics: Anticonvulsants; Bipolar Disorder; Carbamazepine; Clinical Trials as Topic; Clonazepam; Depressive D | 1983 |
Psychopharmacology in child and adolescent psychiatry: a review of the past seven years. Part II.
Topics: Adolescent; Alprazolam; Anticonvulsants; Antipsychotic Agents; Anxiety, Separation; Bipolar Disorder | 1995 |
Rational polypharmacy in the treatment of mood disorders.
Topics: Antidepressive Agents, Tricyclic; Antipsychotic Agents; Benzodiazepines; Carbamazepine; Depressive D | 1993 |
The rationale for long-term antidepressant therapy.
Topics: Antidepressive Agents; Bipolar Disorder; Carbamazepine; Clinical Trials as Topic; Depressive Disorde | 1993 |
Management of psychotic, treatment-resistant depression.
Topics: Affect; Affective Disorders, Psychotic; Antidepressive Agents; Antipsychotic Agents; Carbamazepine; | 1996 |
Additive effects, but no synergistic interaction of stressful life-events and genetic loading in affective disorders.
Topics: Age of Onset; Aged; Antimanic Agents; Bipolar Disorder; Carbamazepine; Depressive Disorder; Female; | 1996 |
The use of anticonvulsants to augment antidepressant medication.
Topics: Adult; Ambulatory Care; Amitriptyline; Anticonvulsants; Antidepressive Agents; Carbamazepine; Clinic | 1998 |
Mood-stabilizing drugs in depression.
Topics: Acute Disease; Anticonvulsants; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Bipolar Diso | 1999 |
[Acute renal failure complicating carbamazepine hypersensitivity].
Topics: Acute Kidney Injury; Carbamazepine; Creatinine; Depressive Disorder; Drug Hypersensitivity; Eosinoph | 1992 |
Drug treatment of bipolar depression and mania.
Topics: Antidepressive Agents; Antipsychotic Agents; Bipolar Disorder; Bromocriptine; Carbamazepine; Choline | 1985 |
Treatment of the cardiac-impaired depressed patient. Part II: Lithium, carbamazepine, and electroconvulsive therapy.
Topics: Arrhythmias, Cardiac; Carbamazepine; Clinical Trials as Topic; Depressive Disorder; Electroconvulsiv | 1988 |
Time course of clinical effects of carbamazepine: implications for mechanisms of action.
Topics: Affect; Bipolar Disorder; Carbamazepine; Depressive Disorder; Humans; Sleep; Time Factors | 1988 |
36 trials available for carbamazepine and Depression, Endogenous
| Article | Year |
|---|---|
Evaluating response to mood stabilizers in patients with mixed depression: A study of agreement between three different mania rating scales and a depression rating scale.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Carbamazepine; Depressive Disorder; Diagnostic and Statis | 2016 |
A multicenter, randomized, double-blind, placebo-controlled trial of extended-release carbamazepine capsules as monotherapy for bipolar disorder patients with manic or mixed episodes.
Topics: Acute Disease; Adult; Antimanic Agents; Bipolar Disorder; Carbamazepine; Delayed-Action Preparations | 2004 |
The effectiveness of carbamazepine in unipolar depression: a double-blind, randomized, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Carbamazepine; Depressive Disorder; Diagnostic and S | 2008 |
Biochemical effects of carbamazepine: relationship to its mechanisms of action in affective illness.
Topics: Bipolar Disorder; Brain; Carbamazepine; Clinical Trials as Topic; Depressive Disorder; Double-Blind | 1983 |
Profile of clinical efficacy and side effect of carbamazepine in psychiatric illness: relationship to blood and CSF levels of carbamazepine and its -10,11-epoxide metabolite.
Topics: Biotransformation; Bipolar Disorder; Carbamazepine; Clinical Trials as Topic; Depressive Disorder; D | 1984 |
Treatment of mood disorders with antiepileptic medications: clinical and theoretical implications.
Topics: Anticonvulsants; Bipolar Disorder; Carbamazepine; Clinical Trials as Topic; Clonazepam; Depressive D | 1983 |
Addition of monoamine oxidase inhibitors to carbamazepine: preliminary evidence of safety and antidepressant efficacy in treatment-resistant depression.
Topics: Adult; Bipolar Disorder; Carbamazepine; Depressive Disorder; Double-Blind Method; Drug Administratio | 1995 |
Effects of the antidepressant drug viloxazine on oxcarbazepine and its hydroxylated metabolites in patients with epilepsy.
Topics: Adult; Anticonvulsants; Carbamazepine; Cross-Over Studies; Depressive Disorder; Double-Blind Method; | 1994 |
Rash complicating carbamazepine treatment.
Topics: Adult; Anxiety Disorders; Bipolar Disorder; Carbamazepine; Depressive Disorder; Double-Blind Method; | 1994 |
Carbamazepine increases cerebrospinal fluid thyrotropin-releasing hormone levels in affectively ill patients.
Topics: Adult; Carbamazepine; Depressive Disorder; Double-Blind Method; Female; Hospitalization; Humans; Mal | 1994 |
Carbamazepine in the prophylaxis of major depression: a 5-year follow-up.
Topics: Adult; Ambulatory Care; Carbamazepine; Depressive Disorder; Drug Administration Schedule; Female; Fo | 1994 |
The comparative efficacy of carbamazepine low and high serum level and lithium carbonate in the prophylaxis of affective disorders.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Carbamazepine; Delayed-Action Preparations; Depressive Di | 1993 |
The recruitment process for a multicenter study on the long-term prophylactic treatment of affective disorders.
Topics: Adult; Affective Disorders, Psychotic; Amitriptyline; Bipolar Disorder; Carbamazepine; Depressive Di | 1993 |
Carbamazepine but not valproate induces bupropion metabolism.
Topics: Adult; Antidepressive Agents; Biotransformation; Bipolar Disorder; Bupropion; Carbamazepine; Cytochr | 1995 |
Personality differences between patients with major depression and bipolar disorder--the impact of minor symptoms on self-ratings of personality.
Topics: Adult; Aged; Amitriptyline; Bipolar Disorder; Carbamazepine; Defense Mechanisms; Depressive Disorder | 1997 |
Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder.
Topics: Adult; Aged; Ambulatory Care; Bipolar Disorder; Carbamazepine; Cross-Over Studies; Depressive Disord | 1997 |
5-HT brain function in affective disorder: d,l-fenfluramine-induced hormone release and clinical outcome in long-term lithium/carbamazepine prophylaxis.
Topics: Adult; Affective Disorders, Psychotic; Carbamazepine; Depressive Disorder; Female; Fenfluramine; Hum | 1997 |
Effect of carbamazepine on pain scores of unipolar depressed patients with chronic pain: a trial of off-on-off-on design.
Topics: Adult; Aged; Analgesics, Non-Narcotic; Carbamazepine; Chronic Disease; Depressive Disorder; Drug Adm | 1998 |
Nimodipine monotherapy and carbamazepine augmentation in patients with refractory recurrent affective illness.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Calcium Channel Blockers; Carbamazepine; Depressive Disor | 1998 |
Potentiation of antidepressants with lithium or carbamazepine in treatment-resistant depression.
Topics: Adenosine Triphosphatases; Adult; Aged; Anti-Inflammatory Agents; Anticonvulsants; Antidepressive Ag | 1999 |
Pharmacokinetic interaction between imipramine and carbamazepine in patients with major depression.
Topics: Antidepressive Agents, Tricyclic; Antimanic Agents; Biotransformation; Carbamazepine; Depressive Dis | 2001 |
Carbamazepine treatment in patients discontinuing long-term benzodiazepine therapy. Effects on withdrawal severity and outcome.
Topics: Benzodiazepines; Carbamazepine; Depressive Disorder; Diazepam; Double-Blind Method; Female; Humans; | 1991 |
Spectrum of efficacy of valproate in 55 patients with rapid-cycling bipolar disorder.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Carbamazepine; Clinical Trials as Topic; Depressive | 1990 |
Addition of lithium carbonate to carbamazepine: hematological and thyroid effects.
Topics: Adult; Blood Cell Count; Carbamazepine; Clinical Trials as Topic; Depressive Disorder; Double-Blind | 1990 |
Carbamazepine prophylaxis in refractory affective disorders: a focus on long-term follow-up.
Topics: Adult; Bipolar Disorder; Carbamazepine; Depressive Disorder; Drug Therapy, Combination; Female; Foll | 1990 |
Carbamazepine in the prophylaxis of mood disorders.
Topics: Adult; Aged; Bipolar Disorder; Carbamazepine; Depressive Disorder; Female; Follow-Up Studies; Humans | 1990 |
The addition of lithium to carbamazepine. Antidepressant efficacy in treatment-resistant depression.
Topics: Adult; Antidepressive Agents; Carbamazepine; Clinical Trials as Topic; Depressive Disorder; Double-B | 1989 |
Effects of carbamazepine on cerebrospinal fluid somatostatin.
Topics: Adrenocorticotropic Hormone; Bipolar Disorder; Carbamazepine; Depressive Disorder; gamma-Aminobutyri | 1985 |
PTSD and carbamazepine.
Topics: Carbamazepine; Clinical Trials as Topic; Combat Disorders; Depressive Disorder; Dexamethasone; Human | 1988 |
Treatment of the cardiac-impaired depressed patient. Part II: Lithium, carbamazepine, and electroconvulsive therapy.
Topics: Arrhythmias, Cardiac; Carbamazepine; Clinical Trials as Topic; Depressive Disorder; Electroconvulsiv | 1988 |
The comparative efficacy and safety of carbamazepine versus lithium: a randomized, double-blind 3-year trial in 83 patients.
Topics: Adult; Carbamazepine; Clinical Trials as Topic; Depressive Disorder; Double-Blind Method; Female; Hu | 1986 |
Pharmacotherapy of borderline personality disorder. Alprazolam, carbamazepine, trifluoperazine, and tranylcypromine.
Topics: Adult; Alprazolam; Ambulatory Care; Borderline Personality Disorder; Carbamazepine; Clinical Trials | 1988 |
Antidepressant effects of carbamazepine.
Topics: Adult; Bipolar Disorder; Carbamazepine; Clinical Trials as Topic; Depressive Disorder; Double-Blind | 1986 |
Development of melancholia during carbamazepine treatment in borderline personality disorder.
Topics: Adult; Borderline Personality Disorder; Carbamazepine; Clinical Trials as Topic; Depressive Disorder | 1986 |
Carbamazepine for treatment-resistant depressions?
Topics: Bipolar Disorder; Carbamazepine; Clinical Trials as Topic; Depressive Disorder; Humans | 1986 |
Carbamazepine in bipolar illness.
Topics: Bipolar Disorder; Carbamazepine; Clinical Trials as Topic; Depressive Disorder; Double-Blind Method; | 1985 |
118 other studies available for carbamazepine and Depression, Endogenous
| Article | Year |
|---|---|
Depressive disorders in patients with pharmaco-resistant mesial temporal lobe epilepsy.
Topics: Adult; Anticonvulsants; Antidepressive Agents; Benzodiazepines; Carbamazepine; Clobazam; Depressive | 2018 |
Nociceptin/orphanin FQ receptor agonists increase aggressiveness in the mouse resident-intruder test.
Topics: Aggression; Agonistic Behavior; Animals; Anxiety; Bipolar Disorder; Carbamazepine; Cycloheptanes; De | 2019 |
[Temporal lobe epilepsy and active neurocysticercosis: two representative case reports].
Topics: Albendazole; Anomia; Anthelmintics; Anticonvulsants; Antipsychotic Agents; Carbamazepine; Citalopram | 2015 |
Moclobemide monotherapy vs. combined therapy with valproic acid or carbamazepine in depressive patients: a pharmacokinetic interaction study.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antimanic Agents; Carbamazepine; Case-Control Studie | 2009 |
New-onset vascular mania in a patient with chronic depression.
Topics: Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Dementia, Vascular; Depress | 2009 |
Localisation value of ictal arterial spin-labelled sequences in partial seizures.
Topics: Adult; Anticonvulsants; Brain Injuries; Carbamazepine; Depressive Disorder; Diffusion Magnetic Reson | 2011 |
Follicular mucinosis in a mycosis fungoides-like hypersensitivity syndrome induced by oxcarbamazepine.
Topics: Antimanic Agents; Carbamazepine; Depressive Disorder; Drug Hypersensitivity; Female; Humans; Middle | 2011 |
Response to nimodipine in ultradian bipolar cycling after amygdalohippocampectomy.
Topics: Antimanic Agents; Bipolar Disorder; Calcium Channel Blockers; Carbamazepine; Depressive Disorder; Fe | 2012 |
Women with PTSD: the psychodynamic aspects of psychopharmacologic and "hands-on" psychiatric management.
Topics: Adult; Anticonvulsants; Antidepressive Agents, Second-Generation; Carbamazepine; Combined Modality T | 2002 |
Oxcarbazepine vs. valproate in the treatment of mood and schizoaffective disorders.
Topics: Adult; Akathisia, Drug-Induced; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Brief Psychiatr | 2003 |
Combination therapy with venlafaxine and carbamazepine in depressive patients not responding to venlafaxine: pharmacokinetic and clinical aspects.
Topics: Adolescent; Adult; Aged; Alleles; Antidepressive Agents, Second-Generation; Carbamazepine; Cyclohexa | 2004 |
Drug treatments for bipolar disorder: 1--Acute manic or depressive episodes.
Topics: Adult; Anticonvulsants; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Bipolar Disor | 2005 |
Cotard's syndrome in adolescents and young adults: a possible onset of bipolar disorder requiring a mood stabilizer?
Topics: Adolescent; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Body Image; Carbamazepine; Delusion | 2005 |
Nonconvulsive status epilepticus precipitated by carbamazepine presenting as dissociative and affective disorders in adolescents.
Topics: Adolescent; Adult; Anticonvulsants; Carbamazepine; Depressive Disorder; Diagnosis, Differential; Dia | 2005 |
Fever, eosinophilia, and a rash.
Topics: Adult; Antimanic Agents; Carbamazepine; Depressive Disorder; Diagnosis, Differential; Drug Eruptions | 2006 |
[Psychopharmaceuticals in chronic pain].
Topics: Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Anxiety Disorders; Brain; Carbamazepin | 1981 |
The use of carbamazepine as an adjunctive medication in the treatment of affective disorders: a clinical report.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Depressive Diso | 1984 |
Biological relationships between mania and melancholia.
Topics: Affective Disorders, Psychotic; Antidepressive Agents, Tricyclic; Bipolar Disorder; Carbamazepine; D | 1982 |
The treatment of chronic depression. An illustrative case.
Topics: Carbamazepine; Chronic Disease; Depressive Disorder; Drug Therapy, Combination; Female; Humans; Lith | 1984 |
Effect of carbamazepine on CSF opioid activity; relationship to antidepressant response.
Topics: Carbamazepine; Depressive Disorder; Endorphins; Enkephalins; Humans; Radioligand Assay; Receptors, O | 1981 |
Effect of carbamazepine on cyclic nucleotides in CSF of patients with affective illness.
Topics: Adult; Affective Disorders, Psychotic; Aged; Bipolar Disorder; Carbamazepine; Cyclic AMP; Cyclic GMP | 1982 |
Carbamazepine and lithium carbonate in the treatment of refractory affective disorders.
Topics: Adult; Bipolar Disorder; Carbamazepine; Depressive Disorder; Humans; Lithium; Lithium Carbonate; Mal | 1983 |
Choreoathetosis associated with lithium: case report and literature review.
Topics: Athetosis; Carbamazepine; Chorea; Depressive Disorder; Female; Humans; Lithium; Lithium Carbonate; M | 1983 |
The effects of carbamazepine on the thyrotropin response to thyrotropin-releasing hormone.
Topics: Adult; Bipolar Disorder; Carbamazepine; Depressive Disorder; Female; Humans; Hypothalamo-Hypophyseal | 1984 |
Carbamazepine and thyroid function in affectively ill patients. Clinical and theoretical implications.
Topics: Adult; Carbamazepine; Depressive Disorder; Female; Humans; Male; Middle Aged; Radioimmunoassay; Thyr | 1984 |
Thyroid function and affective illness: a reappraisal.
Topics: Antidepressive Agents, Tricyclic; Bipolar Disorder; Carbamazepine; Depressive Disorder; Electroconvu | 1984 |
Verapamil and depression.
Topics: Bipolar Disorder; Carbamazepine; Depressive Disorder; Drug Therapy, Combination; Dyskinesia, Drug-In | 1984 |
Carbamazepine-induced mania in two children: case report.
Topics: Age Factors; Bipolar Disorder; Carbamazepine; Chemical Phenomena; Chemistry; Child; Depressive Disor | 1984 |
Relationship of response to sleep deprivation and carbamazepine in depressed patients.
Topics: Adult; Carbamazepine; Combined Modality Therapy; Depressive Disorder; Double-Blind Method; Female; H | 1984 |
Thrombocytopenia associated with carbamazepine: case report and review.
Topics: Aged; Blood Cell Count; Carbamazepine; Depressive Disorder; Female; Humans; Mood Disorders; Thromboc | 1984 |
Carbamazepine and its -10,11-epoxide metabolite in plasma and CSF. Relationship to antidepressant response.
Topics: Adult; Aged; Bipolar Disorder; Carbamazepine; Depressive Disorder; Female; Humans; Male; Middle Aged | 1983 |
Rapid cycling.
Topics: Antidepressive Agents, Tricyclic; Bipolar Disorder; Carbamazepine; Depressive Disorder; Humans | 1983 |
Interference by carbamazepine with the dexamethasone suppression test.
Topics: Adolescent; Adult; Bipolar Disorder; Carbamazepine; Depressive Disorder; Dexamethasone; Diagnosis, D | 1982 |
Myoclonus in patients treated with clozapine: a case series.
Topics: Adult; Antipsychotic Agents; Carbamazepine; Clozapine; Depressive Disorder; Diagnosis, Differential; | 1995 |
Maintenance ECT in intractable manic-depressive disorders.
Topics: Adult; Aged; Antidepressive Agents, Tricyclic; Bipolar Disorder; Carbamazepine; Combined Modality Th | 1994 |
Lithium: the present and the future.
Topics: Acute Disease; Bipolar Disorder; Carbamazepine; Depressive Disorder; Drug Interactions; Female; Huma | 1995 |
Blood dyscrasias with carbamazepine and valproate: a pharmacoepidemiological study of 2,228 patients at risk.
Topics: Adolescent; Adult; Anemia; Carbamazepine; Depressive Disorder; Desipramine; Drug Therapy, Combinatio | 1995 |
Three cases of alopecia areata induced by zotepine.
Topics: Adult; Alopecia; Alopecia Areata; Antipsychotic Agents; Autoimmune Diseases; Carbamazepine; Clomipra | 1993 |
Is there any relationship between anticonvulsant and mood-stabilizing effects of carbamazepine?
Topics: Affect; Anticonvulsants; Carbamazepine; Depressive Disorder; Epilepsy, Tonic-Clonic; Female; Humans; | 1994 |
CSF neuroactive steroids in affective disorders: pregnenolone, progesterone, and DBI.
Topics: Adult; Bipolar Disorder; Carbamazepine; Carrier Proteins; Depressive Disorder; Diazepam Binding Inhi | 1994 |
Misdiagnosis of bipolar affective disorder as personality disorder.
Topics: Adult; Amitriptyline; Antidepressive Agents, Tricyclic; Bipolar Disorder; Carbamazepine; Combined Mo | 1993 |
Association of transient SIADH with sertraline.
Topics: 1-Naphthylamine; Carbamazepine; Depressive Disorder; Drug Therapy, Combination; Drug Tolerance; Huma | 1994 |
The role of carbamazepine in the prophylaxis of unipolar depression.
Topics: Carbamazepine; Depressive Disorder; Female; Humans; Lithium; Male; Middle Aged; Psychiatric Status R | 1993 |
Sequential Cotard and Capgras delusions.
Topics: Adult; Brain; Capgras Syndrome; Carbamazepine; Chlorpromazine; Delusions; Depressive Disorder; Elect | 1993 |
Divalproex sodium in the treatment of refractory affective disorders.
Topics: Adult; Aged; Bipolar Disorder; Carbamazepine; Depressive Disorder; Drug Therapy, Combination; Female | 1993 |
Self-esteem in recovered bipolar and unipolar out-patients.
Topics: Adult; Aged; Antidepressive Agents; Bipolar Disorder; Carbamazepine; Combined Modality Therapy; Depr | 1993 |
[Bipolar patients in remission: personality disorders and changes in personality].
Topics: Adult; Bipolar Disorder; Carbamazepine; Cyclothymic Disorder; Depressive Disorder; Female; Hospitali | 1993 |
Identification of treatment-resistant depressives who respond favorably to carbamazepine.
Topics: Adult; Carbamazepine; Depressive Disorder; Dichotic Listening Tests; Epilepsies, Partial; Humans; Ma | 1993 |
Treatment resistant depression in a case of minor head injury: an electrophysiological hypothesis.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Carbamazepine; Cerebral Cortex; Depressive Disorder; | 1993 |
Catatonia associated with depression secondary to complex partial epilepsy.
Topics: Adult; Carbamazepine; Catatonia; Depressive Disorder; Epilepsy, Complex Partial; Female; Humans | 1993 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.
Topics: Affect; Carbamazepine; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Human | 1995 |
MAOI-carbamazepine combination and statistical power.
Topics: Carbamazepine; Depressive Disorder; Drug Interactions; Drug Therapy, Combination; Humans; Monoamine | 1996 |
Carbamazepine augmentation therapy in three patients with trazodone-resistant unipolar depression.
Topics: Aged; Anticonvulsants; Carbamazepine; Depressive Disorder; Drug Resistance; Drug Therapy, Combinatio | 1996 |
Substituting carbamazepine with oxcarbazepine increases citalopram levels. A report on two cases.
Topics: Adult; Anticonvulsants; Antidepressive Agents; Carbamazepine; Citalopram; Depressive Disorder; Drug | 1996 |
Combined valproate or carbamazepine and electroconvulsive therapy.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Carbamazepine; | 1997 |
The treatment of stupor associated with MRI evidence of cerebrovascular disease.
Topics: Aged; Anticonvulsants; Antidepressive Agents; Carbamazepine; Catatonia; Cerebrovascular Disorders; C | 1997 |
Carbamazepine in the treatment of neuroleptic malignant syndrome.
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Carbamazepine; Depressive Disorder; Female; Haloperido | 1998 |
Social adjustment and the course of affective illness: a one-year controlled longitudinal study involving bipolar and unipolar outpatients.
Topics: Adult; Antidepressive Agents; Carbamazepine; Depressive Disorder; Female; Humans; Longitudinal Studi | 1998 |
Effects of medical interventions on suicidal behavior. Summary and conclusions.
Topics: Anticonvulsants; Carbamazepine; Comorbidity; Depressive Disorder; Health Education; Humans; Lithium; | 1999 |
Interaction between trazodone and carbamazepine.
Topics: Anticonvulsants; Antidepressive Agents, Second-Generation; Carbamazepine; Depressive Disorder; Epile | 1999 |
Lack of sertraline efficacy probably due to an interaction with carbamazepine.
Topics: Adult; Anticonvulsants; Carbamazepine; Depressive Disorder; Drug Administration Schedule; Drug Inter | 2000 |
Mood-stabilisers reduce the risk of developing antidepressant-induced maniform states in acute treatment of bipolar I depressed patients.
Topics: Adult; Aged; Antidepressive Agents, Tricyclic; Antimanic Agents; Bipolar Disorder; Carbamazepine; De | 2001 |
Nefazodone may inhibit the metabolism of carbamazepine: three case reports.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Carbamazepine; Depressive Disorder; Female; Huma | 2001 |
Nonadherence with mood stabilizers: prevalence and predictors.
Topics: Adult; Anticonvulsants; Antidepressive Agents; Attitude of Health Personnel; Attitude to Health; Bip | 2002 |
Depressive disorders preceding temporal lobe epilepsy.
Topics: Aged; Amoxapine; Anticonvulsants; Antidepressive Agents; Antidepressive Agents, Second-Generation; C | 2002 |
[Duration of antidepressive treatments].
Topics: Antidepressive Agents, Tricyclic; Bupropion; Carbamazepine; Depressive Disorder; Dose-Response Relat | 1992 |
Carbamazepine addition in tricyclic antidepressant-resistant unipolar depression.
Topics: Aged; Anxiety Disorders; Carbamazepine; Clomipramine; Depressive Disorder; Dose-Response Relationshi | 1992 |
Alopecia and mood stabilizers: two case reports.
Topics: Adult; Alopecia; Carbamazepine; Clorazepate Dipotassium; Depressive Disorder; Female; Fluvoxamine; H | 1992 |
Carbamazepine-induced atrioventricular block.
Topics: Carbamazepine; Depressive Disorder; Female; Heart Block; Humans; Middle Aged | 1992 |
[Brief depressive affect].
Topics: Carbamazepine; Depressive Disorder; Dose-Response Relationship, Drug; Humans; Male; Middle Aged; Psy | 1992 |
The antidepressant effect of carbamazepine in callosal agenesis: a case report.
Topics: Agenesis of Corpus Callosum; Carbamazepine; Depressive Disorder; Female; Humans; Middle Aged | 1992 |
Do monoamine oxidase inhibitors alter carbamazepine blood levels?
Topics: Aged; Carbamazepine; Depressive Disorder; Drug Interactions; Humans; Monoamine Oxidase Inhibitors; P | 1992 |
Carbamazepine for treatment-resistant melancholia.
Topics: Adult; Age Factors; Aged; Antidepressive Agents, Tricyclic; Carbamazepine; Depressive Disorder; Elec | 1991 |
Effects of carbamazepine on serum antidepressant concentrations in psychiatric patients.
Topics: Adult; Age Factors; Amitriptyline; Antidepressive Agents; Bipolar Disorder; Carbamazepine; Depressiv | 1991 |
Political change and course of affective psychoses: Berlin 1989-90.
Topics: Affective Disorders, Psychotic; Berlin; Bipolar Disorder; Carbamazepine; Cross-Sectional Studies; De | 1991 |
Controlling agitation in patients with cognitive impairment.
Topics: Aphasia, Broca; Carbamazepine; Depressive Disorder; Drug Therapy, Combination; Epilepsy, Temporal Lo | 1991 |
Hallucinations controlled with anticonvulsants.
Topics: Carbamazepine; Cerebral Infarction; Depressive Disorder; Electroencephalography; Epilepsy, Temporal | 1991 |
Dichotic listening failure in dysphoric neuropsychiatric patients who endorse multiple seizure-like symptoms.
Topics: Adult; Anxiety Disorders; Auditory Perception; Auditory Threshold; Carbamazepine; Depressive Disorde | 1991 |
A case of depression responding to spontaneous epilepsy but not ECT.
Topics: Aged; Carbamazepine; Cerebral Cortex; Depressive Disorder; Electroconvulsive Therapy; Electroencepha | 1991 |
Cerebral effects of carbamazepine capsules and Divitabs in psychiatric patients.
Topics: Adult; Brain; Capsules; Carbamazepine; Cognition Disorders; Delayed-Action Preparations; Depressive | 1991 |
The effects of carbamazepine on resting metabolic rate and thyroid function in depressed patients.
Topics: Adult; Calorimetry, Indirect; Carbamazepine; Depressive Disorder; Dose-Response Relationship, Drug; | 1991 |
Effects of carbamazepine on dopamine- and serotonin-mediated neuroendocrine responses.
Topics: Adult; Apomorphine; Brain; Carbamazepine; Depressive Disorder; Dopamine; Growth Hormone; Humans; Mal | 1990 |
[Mononucleosis syndrome with hypersensitivity hepatitis following carbamazepine administration].
Topics: Adult; Carbamazepine; Chemical and Drug Induced Liver Injury; Depressive Disorder; Diagnosis, Differ | 1990 |
Decisions in psychopharmacologic treatment.
Topics: Algorithms; Carbamazepine; Cerebrovascular Disorders; Clinical Protocols; Decision Making; Depressiv | 1990 |
Selective response to carbamazepine in a case of organic mood disorder.
Topics: Aged; Carbamazepine; Depressive Disorder; Female; Humans; Neurocognitive Disorders; Phenobarbital; P | 1990 |
Phenobarbital treatment and major depressive disorder in children with epilepsy: a naturalistic follow-up.
Topics: Adolescent; Analysis of Variance; Carbamazepine; Child; Depressive Disorder; Epilepsy; Follow-Up Stu | 1990 |
Interaction of fluoxetine with carbamazepine.
Topics: Carbamazepine; Depressive Disorder; Drug Interactions; Drug Therapy, Combination; Female; Fluoxetine | 1990 |
Mood disorders in the psychoneurologic borderland: three cases of responsiveness to carbamazepine.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Carbamazepine; Depressive Disorder; Drug Therapy, Combinat | 1989 |
Carbamazepine and SIADH.
Topics: Aged; Carbamazepine; Depressive Disorder; Female; Humans; Inappropriate ADH Syndrome; Obsessive-Comp | 1989 |
Maintaining remission in mood disorders.
Topics: Antidepressive Agents, Tricyclic; Bipolar Disorder; Carbamazepine; Depressive Disorder; Dose-Respons | 1989 |
The effect of anticonvulsants on the dexamethasone suppression test.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Carbamazepine; Depressive Disorder; Dexamethasone; Epileps | 1989 |
Refractory rapid cycling unipolar depression responds to lithium and carbamazepine treatment.
Topics: Adult; Bipolar Disorder; Carbamazepine; Depressive Disorder; Drug Therapy, Combination; Female; Huma | 1989 |
Exaggerated corticotrophic cell response to human corticotropin-releasing hormone in two patients during long-term carbamazepine treatment.
Topics: Adrenocorticotropic Hormone; Adult; Bipolar Disorder; Carbamazepine; Corticotropin-Releasing Hormone | 1988 |
CSF somatostatin in affective illness and normal volunteers.
Topics: Bipolar Disorder; Carbamazepine; Depressive Disorder; Desipramine; Humans; Imipramine; Lithium; Lith | 1985 |
Carbamazepine-induced mania with hypersexuality in a 9-year-old boy.
Topics: Bipolar Disorder; Carbamazepine; Child; Child Behavior Disorders; Depressive Disorder; Humans; Male; | 1989 |
Stupor and affective state: alleviation of psychomotor disturbances by lorazepam and recurrence of symptoms after Ro 15-1788.
Topics: Adult; Carbamazepine; Coma; Depressive Disorder; Drug Interactions; Drug Therapy, Combination; Femal | 1987 |
The effects of carbamazepine on two animal models of depression.
Topics: Animals; Carbamazepine; Depressive Disorder; Disease Models, Animal; Haloperidol; Imipramine; Male; | 1987 |
Hematological effects of lithium potentiation of carbamazepine in patients with affective illness.
Topics: Adult; Bipolar Disorder; Blood Cell Count; Carbamazepine; Depressive Disorder; Drug Synergism; Drug | 1988 |
Treatment of periodic depression with carbamazepine.
Topics: Carbamazepine; Depressive Disorder; Dose-Response Relationship, Drug; Female; Humans; Long-Term Care | 1988 |
[New developments in preventive therapy of manic-depressive disease].
Topics: Antidepressive Agents; Carbamazepine; Depressive Disorder; Dose-Response Relationship, Drug; Humans; | 1988 |
Plasma biopterin levels of patients with affective disorders.
Topics: Adult; Biopterins; Bipolar Disorder; Carbamazepine; Depressive Disorder; Drug Therapy, Combination; | 1988 |
Carbamazepine and ECT.
Topics: Carbamazepine; Combined Modality Therapy; Depressive Disorder; Electroconvulsive Therapy; Female; Hu | 1988 |
Carbamazepine and hyponatremia in patients with affective disorder.
Topics: Adult; Aged; Bipolar Disorder; Carbamazepine; Chlorides; Depressive Disorder; Female; Hospitalizatio | 1988 |
Motor activity in depressed patients treated with carbamazepine.
Topics: Adult; Bipolar Disorder; Carbamazepine; Depressive Disorder; Female; Humans; Male; Middle Aged; Moto | 1987 |
A child with right hemisphere deficit syndrome responsive to carbamazepine treatment.
Topics: Brain Diseases; Carbamazepine; Child; Depressive Disorder; Electroencephalography; Humans; Interpers | 1987 |
Differential time course of antidepressant effects after sleep deprivation, ECT, and carbamazepine: clinical and theoretical implications.
Topics: Carbamazepine; Depressive Disorder; Electroconvulsive Therapy; Humans; Sleep Deprivation | 1987 |
Phenobarbital treatment and major depressive disorder in children with epilepsy.
Topics: Adolescent; Carbamazepine; Child; Depressive Disorder; Epilepsy; Humans; Phenobarbital; Suicide, Att | 1987 |
Effect of carbamazepine on body weight in affectively ill patients.
Topics: Adult; Bipolar Disorder; Body Weight; Carbamazepine; Depressive Disorder; Double-Blind Method; Femal | 1986 |
Complex partial seizures in a patient receiving trazodone.
Topics: Carbamazepine; Depressive Disorder; Epilepsy, Temporal Lobe; Erectile Dysfunction; Humans; Male; Mid | 1986 |
Effects of carbamazepine on serum electrolytes in affectively ill patients.
Topics: Adult; Bipolar Disorder; Carbamazepine; Depressive Disorder; Dose-Response Relationship, Drug; Elect | 1986 |
Carbamazepine and hyponatremia.
Topics: Carbamazepine; Depressive Disorder; Diuretics; Drug Therapy, Combination; Female; Humans; Hyponatrem | 1986 |
Carbamazepine-viloxazine interaction in patients with epilepsy.
Topics: Adult; Carbamazepine; Depressive Disorder; Drug Interactions; Drug Therapy, Combination; Epilepsy; F | 1986 |
Dexamethasone bioavailability: implications for DST research.
Topics: Biological Availability; Carbamazepine; Cushing Syndrome; Depressive Disorder; Dexamethasone; Humans | 1987 |
[Long-term administration of antidepressive agents: maintenance therapy and phase prevention].
Topics: Antidepressive Agents, Tricyclic; Carbamazepine; Depressive Disorder; Humans; Lithium; Long-Term Car | 1985 |
Undetected affective disorder in the developmentally retarded.
Topics: Adult; Carbamazepine; Depressive Disorder; Humans; Intellectual Disability; Male; Mood Disorders | 1986 |
Dopaminergic effects of carbamazepine. Relationship to clinical response in affective illness.
Topics: Adult; Animals; Carbamazepine; Depressive Disorder; Dopamine; Female; Homovanillic Acid; Humans; Mal | 1986 |
Successful treatment of psychotic depression with carbamazepine.
Topics: Adult; Affective Disorders, Psychotic; Carbamazepine; Depressive Disorder; Female; Humans | 1985 |
Efficacy of carbamazepine as an antidepressant in chronic resistant depressives.
Topics: Adult; Aged; Carbamazepine; Chronic Disease; Depressive Disorder; Drug Resistance; Female; Humans; M | 1985 |